Details of the Drug

General Information of Drug (ID: DMMWZET)

• Drug Name: Dexamethasone
• Synonyms: Adexone; Anaflogistico; Aphtasolon; Aphthasolone; Auxiron; Azium; Calonat; Corson; Corsone; Cortisumman; DXM; Decacort; Decacortin; Decaderm; Decadron; Decagel; Decaject; Decalix; Decameth; Decasone; Decaspray; Dectancyl; Dekacort; Deltafluorene; Dergramin; Deronil; Desadrene; Desametasone; Desamethasone; Desameton; Deseronil; Dexacort; Dexacortal; Dexacortin; Dexadeltone; Dexafarma; Dexair; Dexalona; Dexaltin; Dexametasona; Dexameth; Dexamethansone; Dexamethasonum; Dexamethazone; Dexamonozon; Dexapolcort; Dexaprol; Dexason; Dexasone; Dexinolon; Dexinoral; Dexone; Dexonium; Dexpak; Dextelan; Dezone; Dinormon; Dxms; Fluormethylprednisolone; Fluormone; Fluorocort; Fortecortin; Gammacorten; Hexadecadrol; Hexadrol; IontoDex; Loverine; Luxazone; Maxidex; Mediamethasone; Methylfluorprednisolone; Mexidex; Millicorten; Mymethasone; Oradexon; Policort; Posurdex; Prodex; Spoloven; Superprednol; Turbinaire; Visumetazone; Alcon Brand of Dexamethasone; Bisu DS; Desametasone [DCIT]; Dexa Mamallet; Dexamethasone Base; Dexamethasone Intensol; Dexamethasone alcohol; ECR Brand of Dexamethasone; Foy Brand of Dexamethasone; Hexadrol Elixir; Hexadrol Tablets; ICN Brand of Dexamethasone; Lokalison F; Merck Brand of Dexamethasone; Pet Derm III; Prednisolon F; Prednisolone F; Sunia Sol D; Dexone 4; MK 125; Merz Brand 1 of Dexamethasone; Merz Brand 2 of Dexamethasone; Aeroseb-D; Aeroseb-Dex; Azium (Veterinary); Decadron (TN); Decadron Tablets, Elixir; Decadron, Dexamethasone; Decadron-LA; Dex-ide; Dexa-Cortidelt;Dexa-Cortisyl; Dexa-Mamallet; Dexa-Scheroson; Dexa-sine; Dexacen-4; Dexametasona [INN-Spanish]; Dexamethasonum [INN-Latin]; Dexone 0.5; Dexone 0.75; Dexone 1.5; Hl-dex; Isopto-Dex; OTO-104; Ocu-trol;Pet-Derm Iii; SK-Dexamethasone; Decaject L.A.; Dexamethasone [INN:BAN:JAN]; Decaject-L.A.; Dexamethasone (JP15/USP/INN); Delta1-9alpha-Fluoro-16alpha-methylcortisol; Delta(sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol; (3H)-Dexamethasone; 1-Dehydro-16.alpha.-methyl-9.alpha.-fluorohydrocortisone; 1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone; 16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol; 16-alpha-Methyl-9-alpha-fluoro-delta(sup 1)-hydrocortisone; 16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone; 16-alpha-Methyl-9-alpha-fluoroprednisolone; 16.alpha.-Methyl-9.alpha.-fluoro-1-dehydrocortisol; 16.alpha.-Methyl-9.alpha.-fluoroprednisolone; 16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol; 16alpha-Methyl-9alpha-fluoro-delta(sup 1)-hydrocortisone; 16alpha-Methyl-9alpha-fluoroprednisolone; 9-alpha-Fluoro-16-alpha-methylprednisolone; 9.alpha.-Fluoro-16.alpha.-methylprednisolone; 9A-FLUORO-16BETA-METHYLPREDNISOLONE; 9alpha-Fluoro-16alpha-methylprednisolone

Indication

Disease Entry	ICD 11	Status	REF
Acute adrenal insufficiency	N.A.	Approved	[1]
Acute asthma	CA23	Approved	[1]
Addison disease	5A74.0	Approved	[1]
Allergic otitis media	N.A.	Approved	[1]
Allergic rhinitis	CA08.0	Approved	[1]
Angioedema	4A00.15	Approved	[1]
Articular cartilage disorder	FA34.Y	Approved	[1]
Autoimmune haemolytic anaemia	3A20	Approved	[1]
Blepharoconjunctivitis	N.A.	Approved	[1]
Burkitt lymphoma	N.A.	Approved	[1]
Bursitis	N.A.	Approved	[1]
Central retinal vein occlusion with macular edema	N.A.	Approved	[1]
Cerebral edema	8D60.1	Approved	[1]
Congenital adrenal hyperplasia	5A71.01	Approved	[1]
Corneal abrasion	NA06.4	Approved	[1]
Corneal ulcer	9A76	Approved	[1]
Crohn disease	DD70	Approved	[1]
Dermatitis herpetiformis	EB44	Approved	[1]
Diamond-Blackfan anemia	N.A.	Approved	[1]
Disorder of orbital region	N.A.	Approved	[1]
Epicondylitis	N.A.	Approved	[1]
Erythema multiforme	N.A.	Approved	[1]
Exanthem	N.A.	Approved	[1]
Granuloma annulare	N.A.	Approved	[1]
Inflammatory bowel disease	DD72	Approved	[1]
Keratitis	N.A.	Approved	[1]
Liver cirrhosis	DB93.1	Approved	[1]
Lung cancer	2C25.0	Approved	[1]
Malignant otitis externa caused by Pseudomonas aeruginosa	N.A.	Approved	[1]
Miliary tuberculosis	N.A.	Approved	[1]
Multiple sclerosis	8A40	Approved	[1]
Mycosis fungoides	2B01	Approved	[1]
Nausea	MD90	Approved	[1]
Plasma cell myeloma	2A83.1	Approved	[1]
Primary cutaneous T-cell lymphoma	N.A.	Approved	[1]
Psoriasis	EA90	Approved	[1]
Psoriatic arthritis	FA21	Approved	[1]
Rheumatic heart disease	N.A.	Approved	[1]
Rheumatoid arthritis	FA20	Approved	[2]
Rosacea	ED90.0	Approved	[1]
Sarcoidosis	4B20.5	Approved	[1]
Serum sickness	N.A.	Approved	[1]
Skin disease	EA00-EM0Z	Approved	[1]
Systemic lupus erythematosus	4A40.0	Approved	[1]
Vomiting	MD90	Approved	[1]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 2/3	[3]
Acquired thrombocytopenia	N.A.	Investigative	[1]
Asthma	CA23	Investigative	[1]
B-cell neoplasm	N.A.	Investigative	[1]
Beta-thalassemia major	N.A.	Investigative	[1]
Classic Hodgkin lymphoma	N.A.	Investigative	[1]
Follicular lymphoma	2A80	Investigative	[1]
Iridocyclitis	N.A.	Investigative	[1]
Keloid	EE60	Investigative	[1]
Trichinellosis	N.A.	Investigative	[1]
Uveitis	9A96.Z	Investigative	[1]

• Therapeutic Class: Antiinflammatory Agents
• Affected Organisms: Humans and other mammals
• ATC Code:
  A01AC02: Dexamethasone
  A01AC: Corticosteroids for local oral treatment
  A01A: STOMATOLOGICAL PREPARATIONS
  A01: STOMATOLOGICAL PREPARATIONS
  A: ALIMENTARY TRACT AND METABOLISM
  C05AA09: Dexamethasone
  C05AA: Corticosteroids
  C05A: AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE
  C05: VASOPROTECTIVES
  C: CARDIOVASCULAR SYSTEM
  D07AB19: Dexamethasone
  D07AB: Corticosteroids, moderately potent (group II)
  D07A: CORTICOSTEROIDS, PLAIN
  D07: CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
  D: DERMATOLOGICALS
  D07XB05: Dexamethasone
  D07XB: Corticosteroids, moderately potent, other combinations
  D07X: CORTICOSTEROIDS, OTHER COMBINATIONS
  D07: CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
  D: DERMATOLOGICALS
  D10AA03: Dexamethasone
  D10AA: Corticosteroids, combinations for treatment of acne
  D10A: ANTI-ACNE PREPARATIONS FOR TOPICAL USE
  D10: ANTI-ACNE PREPARATIONS
  D: DERMATOLOGICALS
  H02AB02: Dexamethasone
  H02AB: Glucocorticoids
  H02A: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN
  H02: CORTICOSTEROIDS FOR SYSTEMIC USE
  H: SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
  H02AB02: Dexamethasone
  H02AB: Glucocorticoids
  H02A: CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN
  H02: CORTICOSTEROIDS FOR SYSTEMIC USE
  H: SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
  R01AD03: Dexamethasone
  R01AD: Corticosteroids
  R01A: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
  R01: NASAL PREPARATIONS
  R: RESPIRATORY SYSTEM
  S01BA01: Dexamethasone
  S01BA: Corticosteroids, plain
  S01B: ANTIINFLAMMATORY AGENTS
  S01: OPHTHALMOLOGICALS
  S: SENSORY ORGANS
  S01CB01: Dexamethasone
  S01CB: Corticosteroids/antiinfectives/mydriatics in combination
  S01C: ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION
  S01: OPHTHALMOLOGICALS
  S: SENSORY ORGANS
  S02BA06: Dexamethasone
  S02BA: Corticosteroids
  S02B: CORTICOSTEROIDS
  S02: OTOLOGICALS
  S: SENSORY ORGANS
  S03BA01: Dexamethasone
  S03BA: Corticosteroids
  S03B: CORTICOSTEROIDS
  S03: OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS
  S: SENSORY ORGANS
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 392.5
  Logarithm of the Partition Coefficient (xlogp); 1.9
  Rotatable Bond Count (rotbonds); 2
  Hydrogen Bond Donor Count (hbonddonor); 3
  Hydrogen Bond Acceptor Count (hbondacc); 6
• ADMET Property:
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
  Clearance: The drug present in the plasma can be removed from the body at the rate of 3.3 mL/min/kg [5]
  Elimination: 2.6% of drug is excreted from urine in the unchanged form [4]
  Half-life: The concentration or amount of drug in body reduced by one-half in 3.7 hours [5]
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.3276 micromolar/kg/day [6]
  Unbound Fraction: The unbound fraction of drug in plasma is 0.32% [5]
  Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.94 L/kg [5]
  Water Solubility: The ability of drug to dissolve in water is measured as 0.092 mg/mL [4]

Adverse Drug Reaction (ADR)

ADR Term	Variation	Related DOT	DOT ID	REF
Apoptosis	Not Available	MAPK11	OT0AS010	[7]
Apoptosis	Not Available	PARP1	OTIESHK4	[7]
Apoptosis	Not Available	IFNA7	OTSQ6R46	[7]
Bone disorder	Not Available	CDH4	OT8LH3HN	[7]
Bone disorder	Not Available	CDH12	OTF2HCGA	[7]
Bone disorder	Not Available	CDH11	OTIZKPTF	[7]
Bone disorder	Not Available	ALPP	OTZU4G9W	[7]
Gastrointestinal disorders	Not Available	DDC	OT0TSW09	[7]
Gastrointestinal disorders	Not Available	GAST	OTD0IP9N	[7]
Gastrointestinal disorders	Not Available	hdc	OTM3771T	[7]
Gastrointestinal disorders	Not Available	ODC1	OTNDAGRR	[7]
Injury	Not Available	STAT3	OTAAGKYZ	[7]
Investigations	Not Available	IAPP	OT5Z8ERW	[7]
Multiple myeloma	Not Available	MAPK8IP1	OTDAWAUZ	[7]

• Chemical Identifiers:
  Formula: C22H29FO5
  IUPAC Name: (8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
  Canonical SMILES: C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C
  InChI: InChI=1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1
  InChIKey: UREBDLICKHMUKA-CXSFZGCWSA-N
• Cross-matching ID:
  PubChem CID: 5743
  ChEBI ID: CHEBI:41879
  CAS Number: 50-02-2
  UNII: 7S5I7G3JQL
  DrugBank ID: DB01234
  TTD ID: D0IT2G
  VARIDT ID: DR00215
  INTEDE ID: DR0451
  ACDINA ID: D00185
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Glucocorticoid receptor (NR3C1)	TTYRL6O	GCR_HUMAN	Agonist	[8]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Peptide transporter 1 (SLC15A1)	DT9G7XN	S15A1_HUMAN	Substrate	[9]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[10]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[11]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[12]
Cytochrome P450 3A7 (CYP3A7)	DERD86B	CP3A7_HUMAN	Substrate	[13]
Corticosteroid 11-beta-dehydrogenase 2 (HSD11B2)	DEDH7FP	DHI2_HUMAN	Substrate	[14]
Carboxylesterase 2 (CES2)	DETHCPD	EST2_HUMAN	Substrate	[15]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
1,4-alpha-glucan-branching enzyme (GBE1)	OTK2N05B	GLGB_HUMAN	Gene/Protein Processing	[16]
1-acyl-sn-glycerol-3-phosphate acyltransferase beta (AGPAT2)	OT5I4Y9K	PLCB_HUMAN	Gene/Protein Processing	[16]
1-acyl-sn-glycerol-3-phosphate acyltransferase delta (AGPAT4)	OT5CTQKO	PLCD_HUMAN	Gene/Protein Processing	[16]
1-acylglycerol-3-phosphate O-acyltransferase ABHD5 (ABHD5)	OTY829Z3	ABHD5_HUMAN	Gene/Protein Processing	[16]
11-beta-hydroxysteroid dehydrogenase 1 (HSD11B1)	OTO7FJA9	DHI1_HUMAN	Gene/Protein Processing	[17]
11-beta-hydroxysteroid dehydrogenase type 2 (HSD11B2)	OTHF4H9U	DHI2_HUMAN	Gene/Protein Processing	[18]
2'-5'-oligoadenylate synthase 1 (OAS1)	OT8ZLOCY	OAS1_HUMAN	Gene/Protein Processing	[19]
2'-5'-oligoadenylate synthase-like protein (OASL)	OTZ05YRP	OASL_HUMAN	Gene/Protein Processing	[16]
4-aminobutyrate aminotransferase, mitochondrial (ABAT)	OTXAGR7J	GABT_HUMAN	Gene/Protein Processing	[16]
5'-3' exonuclease PLD3 (PLD3)	OTL07SP2	PLD3_HUMAN	Gene/Protein Processing	[16]

Experimental Cancer Drug Sensitivity Information

Cancer Drug Sensitivity Data Curated from 146 Cell Line(s) in Haematopoietic And Lymphoid Tissue Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
JK1	CTRP2	6.7343	9.0957	4.1934	1.3502
MEC1	CTRP2	8.8042	19.0444	0.8752	10.9091
JM1	CTRP2	4.4177	28.7857	-7.3525	35.4752
HH [Human lymphoma]	CTRP2	-11.2056	8.6765	-13.7996	71.4606
RS4;11	CTRP2	-10.6863	-7.0957	-10.6866	94.5922
MHH-CALL-4	CTRP2	-10.2593	-3.9856	-10.2861	87.8567
OCI-Ly19	CTRP2	-8.7594	-3.9099	-8.7679	85.2752
SUP-B15	CTRP2	-8.5279	-4.2553	-8.5315	85.3768
Karpas-422	CTRP2	-8.3476	14.8115	-13.0437	63.1015
JVM-2	CTRP2	-7.907	-3.0662	-7.9193	81.4623
OCI-Ly10	CTRP2; CTRP1	-7.2096	17.351	-12.9244	60.1178
Kasumi-1	CTRP2	-6.8691	-4.9433	-6.8691	79.2015
BV-173	CTRP2	-5.7141	3.445	-6.3018	65.1497
NALM-6	CTRP2	-5.3816	-0.3374	-5.43	67.6746
SEM	CTRP2	-4.2738	-0.5589	-4.2874	61.7427
697	CTRP2	-4.2706	3.1374	-4.6714	59.6261
KMS-11	CTRP2; CTRP1	-4.1148	25.7538	-13.6623	52.9765
SUP-T11	CTRP2	-4.0718	6.8981	-5.466	56.7925
SK-MM-2	CTRP2	-3.5848	9.704	-5.9565	54.1216
SU-DHL-5	CTRP1	-3.4069	-2.1886	-3.4069	99.456
P12-Ichikawa	CTRP2	-3.2801	-1.0059	-3.2808	55.4504
MOLT-16	CTRP2	-3.1241	3.8986	-3.5854	53.6446
KE-37	CTRP2	-3.076	0.9293	-3.1179	53.9657
MM1.S	CTRP2	-2.9074	14.7872	-7.3914	51.294
RCH-ACV	CTRP2	-2.8372	16.894	-8.2714	50.9911
DB	CTRP2	-2.6808	22.9208	-10.9341	50.4565
RPMI-8226	CTRP2; CTRP1	-2.4549	14.8002	-6.9311	50.0044
HuT 78	CTRP2	-2.427	7.206	-3.7874	49.8442
SU-DHL-6	CTRP2	-2.0184	11.057	-4.8538	48.355
KMS-34	CTRP2	-2.0158	18.4512	-8.1755	48.8668
MOLT-13	CTRP2	-0.7897	24.1139	-9.702	46.4489
Kasumi-2	CTRP2	-0.7482	12.7934	-4.3066	43.8292
OPM-2	CTRP2	-0.4169	24.2443	-9.4156	45.6207
DoHH2	CTRP2	0.3654	17.53	-5.4261	41.6657
NCI-H929	CTRP2	0.4749	14.6517	-3.949	39.8821
KE-97	CTRP2; CTRP1	1.7045	13.1664	-2.0436	33.4712
TALL-1 [Human adult T-ALL]	CTRP2	1.7677	10.8393	-0.8918	30.5324
Pfeiffer	CTRP2	1.9425	25.616	-7.9285	40.2969
P3HR-1	CTRP2; CTRP1	1.9847	11.4971	-0.9796	30.2147
LP-1	CTRP2; CTRP1	2.0492	34.1517	-12.0659	42.5163
KMS-26	CTRP2	2.2434	15.5334	-2.6848	33.3058
CML-T1	CTRP2	2.2464	17.709	-3.748	35.1236
KCL-22	CTRP2	2.5961	14.8046	-2.0009	31.0335
L-1236	CTRP2	3.3582	15.4554	-1.6255	28.3452
MHH-CALL-3	CTRP2	3.5316	41.2495	-14.3338	41.4918
NCO2	CTRP2	3.5444	14.8715	-1.1691	26.7526
ST486	CTRP2	3.5475	30.149	-8.7761	38.1958
CA46	CTRP2	3.68	28.033	-7.6058	36.9524
ME1	CTRP2	4.3755	17.8017	-1.8999	26.7878
BL-70	CTRP2; CTRP1	4.6901	9.0049	2.7707	10.3367
ALL-SIL	CTRP2	4.7719	13.3446	0.6651	18.3523
KMS-28BM	CTRP2	4.9718	16.2719	-0.6299	22.1645
PF-382	CTRP2	4.9948	13.8783	0.5861	18.1783
GDM-1	CTRP2; CTRP1	5.8822	11.1836	2.6526	8.6014
A4/Fukuda	CTRP2	5.9092	24.7637	-4.1042	28.4692
Ci-1	CTRP2	6.1699	7.049	4.7553	0.1553
Hs 611.T	CTRP2	6.231	21.7251	-2.3289	24.2748
HT	CTRP2; CTRP1	6.2381	8.9975	3.9641	2.7589
HEL 92.1.7	CTRP2	6.2418	7.4405	4.6366	0.3839
SU-DHL-10	CTRP2	6.2515	7.2781	4.7032	0.2266
EHEB	CTRP2	6.2645	19.0405	-0.9646	20.6932
OCI-AML-5	CTRP2	6.265	7.4274	4.652	0.3345
KMS-12-BM	CTRP2	6.2799	8.3894	4.2547	1.5597
U-937	CTRP2; CTRP1	6.3366	8.4798	4.2593	1.5511
OCI-Ly3	CTRP2	6.3377	25.2084	-3.9811	27.5261
DEL	CTRP2	6.3624	7.3371	4.7257	0.1477
MOLT-3	CTRP2	6.3802	7.8257	4.5466	0.5406
SET-2	CTRP2	6.3846	7.5787	4.6451	0.295
EB1	CTRP2	6.4526	8.6969	4.2152	1.5288
HD-MY-Z	CTRP2	6.4715	9.3571	3.9294	2.5433
JVM-3	CTRP2	6.4943	8.3491	4.3867	0.9284
CMK	CTRP2	6.5122	7.8914	4.5798	0.3851
A3/Kawakami	CTRP2	6.523	7.6623	4.6702	0.1939
SIG-M5	CTRP2	6.6416	7.6997	4.702	0.1143
NB4	CTRP2	6.6497	7.5772	4.7471	0.062
PL21	CTRP2; CTRP1	6.6647	8.0802	4.5862	0.3407
L-540	CTRP2	6.6699	10.9803	3.2972	4.7324
Karpas-620	CTRP2	6.7203	8.3525	4.4916	0.493
Reh	CTRP2	6.7312	9.0842	4.1967	1.3421
AML-193	CTRP2	6.775	8.2231	4.5641	0.3068
KYO-1	CTRP2	6.7872	7.9992	4.6505	0.1527
Peer	CTRP2	6.8139	11.7369	3.033	5.5785
MC116	CTRP2; CTRP1	6.8382	7.646	4.8026	0.0193
SU-DHL-8	CTRP2	6.863	13.9068	2.0221	9.4818
LAMA-84	CTRP2	6.8635	13.5113	2.2144	8.7322
MOLM-6	CTRP2	6.8706	9.0061	4.2992	0.9204
TF-1	CTRP2	6.8772	8.2005	4.6128	0.1869
HL-60	CTRP2	6.8817	8.0338	4.6731	0.1035
Jurkat	CTRP2	6.9087	9.4746	4.1222	1.4355
Karpas-299	CTRP2	6.9138	8.7615	4.4172	0.5759
MOLP-8	CTRP2	6.9264	17.021	0.543	14.8194
Mono-Mac-1	CTRP2	6.9284	9.0178	4.3219	0.8184
OCI-M1	CTRP2	6.968	8.0808	4.6877	0.0748
HEL	CTRP2	7.0017	8.1233	4.6851	0.0727
KMS-27	CTRP2	7.038	8.2297	4.6617	0.0904
P31/FUJ	CTRP2	7.0734	8.267	4.6614	0.0854
AMO1	CTRP2; CTRP1	7.0748	8.2638	4.6773	0.0858
NU-DUL-1	CTRP2; CTRP1	7.0782	16.9974	0.6775	14.1711
KHM-1B	CTRP2	7.084	17.1635	0.5892	14.4044
OCI-AML-2	CTRP2	7.0956	8.2595	4.6717	0.0727
RPMI-8402	CTRP2	7.1253	10.1019	3.9669	1.7594
OCI-AML-3	CTRP2; CTRP1	7.1286	12.8122	2.7417	6.3653
SU-DHL-4	CTRP2; CTRP1	7.1626	13.3267	2.5194	7.183
Mino	CTRP2	7.3337	14.9901	1.826	9.5344
KMS-18	CTRP2	7.3379	14.513	2.0582	8.646
SU-DHL-1	CTRP2	7.3409	18.0523	0.3409	14.835
RPMI-6666	CTRP2	7.3418	8.8442	4.5587	0.1556
MOLM-16	CTRP2; CTRP1	7.3618	8.7781	4.6031	0.1188
U266B1	CTRP2	7.4114	9.0551	4.5102	0.2062
Daudi	CTRP2	7.4324	25.3721	-3.2044	24.2255
HPB-ALL	CTRP2	7.447	14.5463	2.1157	8.274
L-363	CTRP2	7.4618	8.526	4.707	0.0219
K-562	CTRP2	7.4743	8.8297	4.6108	0.0792
HDLM-2	CTRP2	7.49	15.4347	1.7191	9.7106
KMS-21-BM	CTRP2	7.4928	8.8745	4.6022	0.0845
NU-DHL-1	CTRP2	7.5178	13.7498	2.54	6.561
SUP-HD1	CTRP2	7.5768	15.752	1.6258	9.9335
SR	CTRP2	7.6767	9.0568	4.6043	0.0629
Ri-1	CTRP2	7.738	9.8515	4.3488	0.3783
M-07e	CTRP2	7.7636	9.1582	4.6001	0.0579
Ku812	CTRP2; CTRP1	7.8334	9.327	4.582	0.0757
KMM-1	CTRP2	7.8393	10.8161	4.0219	1.0797
Toledo	CTRP2	7.8473	19.9387	-0.2157	15.8392
JJN-3	CTRP2	7.969	20.6654	-0.4832	16.4713
SKM-1	CTRP2; CTRP1	8.0065	15.9701	1.8209	8.6845
THP-1	CTRP2; CTRP1	8.0924	9.667	4.557	0.0687
NOMO-1	CTRP2; CTRP1	8.3106	21.6883	-0.7263	16.7296
F-36P	CTRP2	8.3994	19.2468	0.5073	12.6976
GA-10	CTRP2	8.4936	32.5101	-5.9306	27.5435
WSU-DLCL2	CTRP2; CTRP1	8.6409	25.7301	-2.4647	20.7929
Raji	CTRP2	8.6763	20.972	-0.1335	14.3634
L-428	CTRP2	8.7224	22.1611	-0.6763	15.9315
SUP-M2	CTRP2	8.7919	22.8304	-0.9521	16.6243
Namalwa	CTRP2	8.7948	20.8015	0.0299	13.6872
REC-1	CTRP2	9.1923	18.9655	1.1623	9.4374
KM-H2	CTRP2	9.4171	18.9014	1.3323	8.5877
MOTN-1	CTRP2	9.8236	29.7145	-3.5701	21.5391
SUP-T1	CTRP2	10.0293	47.3268	-12.0997	32.6397
RL	CTRP2	10.0344	33.0009	-5.0248	24.026
KO52	CTRP2	10.1732	33.8016	-5.3161	24.3495
EJM	CTRP2; CTRP1	10.249	19.7221	1.4678	7.2669
DND-41	CTRP2	10.349	50.7333	-13.5439	33.4527
KMS-20	CTRP2	10.3966	24.0142	-0.4371	13.0094
JeKo-1	CTRP2	10.8932	23.7889	-0.0178	11.182
MOLP-2	CTRP2	11.0328	24.395	-0.2123	11.5968
Granta-519	CTRP2	11.0394	31.7218	-3.6889	20.2295

Cancer Drug Sensitivity Data Curated from 24 Cell Line(s) in Oesophagus Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
TE15	CTRP2	7.4171	8.9104	4.563	0.1359
TE8	CTRP2	10.4839	25.0576	-0.8731	14.1454
TE-4	CTRP2	6.2587	8.5317	4.1787	1.8566
TE-6	CTRP2	6.8212	10.0114	3.8388	2.4938
KYSE-150	CTRP2	6.8405	7.9765	4.6781	0.1051
TE-9	CTRP2	7.0466	8.4146	4.6005	0.1632
KYSE-410	CTRP2; CTRP1	7.0947	9.0876	4.3833	0.6081
KYSE-30	CTRP2	7.1055	8.3878	4.6314	0.1121
TE-11	CTRP2	7.2012	9.2497	4.3531	0.5859
KYSE-70	CTRP2	7.2033	9.6518	4.1944	0.9994
TE-14	CTRP2	7.2193	9.533	4.2498	0.8373
KYSE-520	CTRP2	7.2963	14.544	2.015	8.8701
OE19	CTRP2	7.2993	8.5173	4.6554	0.0627
TE-1	CTRP2	7.3907	9.5182	4.3313	0.5479
EC-GI-10	CTRP2	7.5044	8.8479	4.6151	0.0723
TE-5	CTRP2	7.5616	15.1191	1.919	8.8594
COLO 680N	CTRP2	7.7534	9.1978	4.5834	0.0705
OE33	CTRP2	7.8047	15.8621	1.727	9.2388
KYSE-510	CTRP2	7.8729	9.2481	4.6072	0.0452
KYSE-140	CTRP2; CTRP1	7.9046	9.8815	4.4164	0.2481
TE-10	CTRP2	8.3518	10.1726	4.4624	0.1011
OE21	CTRP2	11.2092	26.284	-0.9825	13.5716
KYSE-180	CTRP2	14.1339	28.0273	-0.0481	8.0559
KYSE-450	CTRP2; CTRP1	16.3314	39.3506	-3.852	15.01

Cancer Drug Sensitivity Data Curated from 37 Cell Line(s) in Pancreas Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
N2a-PK1	CTRP2	14.3113	29.8936	-0.7715	9.8031
TCC-Pan2	CTRP2	6.3411	8.3958	4.2861	1.3899
SNU-213	CTRP2	6.6362	8.0457	4.5735	0.3432
SU.86.86	CTRP2	6.7349	8.0623	4.6075	0.2379
KP-2	CTRP2	6.8178	8.4543	4.4945	0.4388
MIA PaCa-2	CTRP2	6.8226	8.2996	4.555	0.3072
KP-4	CTRP2	6.8463	8.2024	4.6001	0.2161
PaTu 8988t	CTRP2	6.8522	8.5167	4.4853	0.4439
HuP-T3	CTRP2	6.9523	10.9377	3.4952	3.6189
KP-3	CTRP2; CTRP1	6.9559	10.4218	3.7448	2.7574
YAPC	CTRP2	7.0555	8.2388	4.6647	0.0847
PaTu 8902	CTRP2; CTRP1	7.0982	8.5329	4.592	0.1872
SUIT-2	CTRP2; CTRP1	7.1963	8.3376	4.6946	0.056
Panc 02.03	CTRP2	7.227	8.8511	4.513	0.2505
PSN1	CTRP2	7.231	9.0626	4.4369	0.3891
L3.3	CTRP2	7.2544	8.404	4.6779	0.0507
SW1990	CTRP2	7.2904	9.8132	4.1701	1.0116
HPAF-II	CTRP2	7.3367	9.2462	4.4115	0.4
Panc 10.05	CTRP2; CTRP1	7.3651	8.8028	4.5958	0.1265
DAN-G	CTRP2	7.3755	8.6085	4.6511	0.0582
QGP-1	CTRP2; CTRP1	7.3805	8.5055	4.7013	0.0364
AsPC-1	CTRP2	7.42	10.2501	4.0535	1.2599
Capan-1	CTRP2	7.6708	9.2705	4.53	0.1298
Capan-2	CTRP2; CTRP1	7.7022	14.6099	2.2657	7.4284
Panc 04.03	CTRP2	7.7239	9.0968	4.607	0.0568
CFPAC-1	CTRP2; CTRP1	7.8892	9.4582	4.5572	0.0894
PK-59	CTRP2	7.9392	9.5892	4.5159	0.1049
Panc 08.13	CTRP2	7.9551	9.8856	4.4196	0.2093
BxPC-3	CTRP2	8.0072	9.9084	4.4307	0.1848
Panc 03.27	CTRP2; CTRP1	8.3599	15.1372	2.4327	5.9994
SNU-410	CTRP2	8.7203	28.6832	-3.8689	23.6569
Panc 05.04	CTRP2	9.8579	19.3851	1.3776	7.9305
PaTu 8988s	CTRP2	11.0075	40.0265	-7.7602	26.9895
PK-45H	CTRP2	11.3882	27.8773	-1.617	15.0382
HPAC	CTRP2; CTRP1	11.5274	22.8906	0.7823	8.1305
HuP-T4	CTRP2; CTRP1	11.7897	21.5497	1.5169	5.653
Hs 766T	CTRP2	12.1843	32.3966	-3.2368	17.9178

Cancer Drug Sensitivity Data Curated from 49 Cell Line(s) in Skin Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
SH4	CTRP2	7.0618	12.951	2.6196	6.8617
SK-MEL-1	CTRP2; CTRP1	5.8173	10.6626	2.8612	7.8541
A101D	CTRP2	6.2438	8.0738	4.3739	1.1797
K029AX	CTRP2	6.3445	8.2536	4.3499	1.1699
A2058	CTRP2	6.3839	7.4556	4.6909	0.2021
CJM [Human melanoma]	CTRP2	6.4346	7.4399	4.7164	0.1426
WM266-4	CTRP2	6.4659	8.354	4.3703	1.0019
SK-MEL-2	CTRP2	6.4864	7.3411	4.77	0.0629
SK-MEL-30	CTRP2	6.4883	10.4845	3.4131	4.5181
WM1799	CTRP2	6.4977	9.2072	4.0132	2.204
SK-MEL-28	CTRP2; CTRP1	6.4999	7.3762	4.7771	0.0706
RVH-421	CTRP2	6.5331	8.7924	4.2174	1.4465
Hs 895.T	CTRP2	6.5516	7.9915	4.5581	0.4172
WM88	CTRP2	6.6876	9.2676	4.0939	1.7253
IGR-37	CTRP2	6.6917	7.8095	4.6819	0.1304
Hs 688(A).T	CTRP2	6.8001	7.9981	4.6557	0.1423
MDA-MB-435S	CTRP2	6.8036	8.3768	4.5181	0.3921
IPC-298	CTRP2	6.8158	7.9253	4.6869	0.0993
Hs 294T	CTRP2	6.838	8.1034	4.6326	0.1667
Hs 936.T	CTRP2; CTRP1	6.8502	8.4957	4.5063	0.4361
SK-MEL-3	CTRP2	6.851	8.2865	4.5713	0.2657
SK-MEL-31	CTRP2	6.8956	8.2758	4.5927	0.2141
WT2-iPS	CTRP2	6.9009	8.0695	4.6677	0.1064
COLO 741	CTRP2; CTRP1	6.9147	9.1778	4.2633	1.047
G-361	CTRP2; CTRP1	6.9264	9.0586	4.3179	0.88
HMCB	CTRP2	6.935	7.8538	4.7523	0.0301
Mel Ho	CTRP2	6.9623	11.1294	3.4129	3.9184
WM115	CTRP2	6.981	12.6991	2.6858	6.7143
SK-MEL-5	CTRP2; CTRP1	7.0211	8.3435	4.6303	0.1509
IGR-1	CTRP2	7.0744	14.6857	1.7928	10.0433
Mel JuSo	CTRP2	7.1282	8.4014	4.6349	0.1045
IGR-39	CTRP2	7.13	8.3183	4.6639	0.0754
RPMI-7951	CTRP2	7.1525	8.6697	4.5497	0.2122
WM793	CTRP2	7.1994	8.8385	4.5068	0.2691
LOX-IMVI	CTRP2	7.2127	9.319	4.3313	0.6327
Hs 852.T	CTRP2; CTRP1	7.311	8.7311	4.6011	0.1299
Hs 940.T	CTRP2	7.4223	9.0746	4.5074	0.2077
COLO 800	CTRP2	7.4359	8.8838	4.5789	0.115
A-375	CTRP2; CTRP1	7.4847	8.8526	4.6211	0.0833
MeWo	CTRP2	7.4972	9.2729	4.465	0.2528
Hs 944.T	CTRP2; CTRP1	7.5373	9.1491	4.538	0.1637
HT-144	CTRP2	7.5609	9.2618	4.493	0.196
SK-MEL-24	CTRP2	7.7004	8.9722	4.6403	0.039
COLO 829	CTRP2	7.8584	9.7838	4.4195	0.2307
WM983B	CTRP2	8.8497	17.9932	1.4	9.043
Hs 839.T	CTRP2	9.0556	18.1597	1.4519	8.6086
COLO 792	CTRP2	10.199	23.1974	-0.1799	12.4926
UACC-62	CTRP2	11.6414	21.2164	1.5689	5.5713
UACC-257	CTRP2	12.8604	28.4594	-0.9685	11.7173

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Ascites Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
COLO 684	CTRP2	7.1402	10.1345	3.9608	1.7667

Cancer Drug Sensitivity Data Curated from 12 Cell Line(s) in Autonomic Ganglia Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
CHP-126	CTRP2	6.3298	8.1999	4.3653	1.1315
SK-N-DZ	CTRP2	6.5478	7.6966	4.6675	0.1911
IMR-32	CTRP2	6.8294	7.8847	4.7057	0.0769
NH-6	CTRP2	6.8911	9.7627	3.9884	1.8966
KP-N-SI9s	CTRP2	6.9213	8.346	4.5772	0.2326
Kelly	CTRP2	7.0015	8.3823	4.595	0.1819
SK-N-AS	CTRP2	7.2241	8.4798	4.642	0.0831
SK-N-FI	CTRP2	7.3138	9.0085	4.4897	0.2641
SK-N-BE(2)	CTRP2	7.3708	10.1451	4.0729	1.2372
NB1	CTRP2	7.439	8.7983	4.6092	0.085
SK-N-SH	CTRP2	7.5506	9.2822	4.4819	0.2139
KP-N-YN	CTRP2	8.7732	18.6904	1.0225	10.4481

Cancer Drug Sensitivity Data Curated from 6 Cell Line(s) in Biliary Tract Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
SNU-1079	CTRP2	-1.7575	16.3447	-6.9405	48.0035
SNU-869	CTRP2	7.2374	8.7209	4.5634	0.1714
HuCC-T1	CTRP2	7.3407	8.8504	4.5561	0.1591
SNU-1196	CTRP2	7.5399	8.9398	4.5965	0.0837
SNU-478	CTRP2	8.3815	22.1225	-0.8986	17.0692
SNU-308	CTRP2	8.3913	16.6942	1.7167	8.4983

Cancer Drug Sensitivity Data Curated from 15 Cell Line(s) in Bone Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
Hs 888.T	CTRP2	3.0637	15.8811	-2.1018	30.1374
TC71	CTRP2	5.9553	8.4681	4.0192	2.8358
SK-N-MC	CTRP2	6.7508	7.5974	4.775	0.0304
A-673	CTRP2	6.7772	8.0237	4.6379	0.1741
SW1353	CTRP2	7.0717	8.7009	4.5067	0.3109
CAL-78	CTRP2	7.1964	8.6608	4.5694	0.1724
SK-ES-1	CTRP2	7.2736	15.6863	1.4474	11.0398
HOS	CTRP2	7.4495	9.0609	4.5224	0.1805
SJSA-1	CTRP2	7.4632	9.0903	4.5171	0.1847
MHH-ES-1	CTRP2	7.5569	9.3011	4.4776	0.2186
G-292 clone A141B1	CTRP2	7.648	9.4239	4.4682	0.2107
SaOS-2	CTRP2	7.8775	9.529	4.5148	0.1142
MG-63	CTRP2	9.7488	48.3803	-12.8387	33.5266
Hs 822.T	CTRP2	11.5451	28.5178	-1.8175	15.3609
U2OS	CTRP2; CTRP1	11.6117	24.5521	0.0806	10.1475

Cancer Drug Sensitivity Data Curated from 68 Cell Line(s) in Breast Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
MDA-MB-468	CTRP2	5.8531	7.7771	4.2788	1.951
ZR-75-1	CTRP2	6.0485	8.3333	4.1424	2.2351
KPL-1	CTRP2	6.0885	6.773	4.8231	0.0714
DU4475	CTRP2	6.3117	7.8529	4.5029	0.7104
Hs 578Bst	CTRP2	6.3996	9.2082	3.9542	2.5328
HMC-1-8	CTRP2	6.5149	7.8305	4.6042	0.3283
CAL-148	CTRP2	6.6543	8.314	4.4773	0.5643
HCC1419	CTRP2	6.6941	8.5	4.4212	0.6905
HCC202	CTRP2	6.9019	10.0023	3.8888	2.2326
ZR-75-30	CTRP2	6.9295	9.0446	4.3115	0.8465
BT-474	CTRP2	6.9661	8.4543	4.5554	0.2569
MDA-MB-361	CTRP2	6.9663	8.8569	4.4031	0.5835
HCC1500	CTRP2	6.9715	8.613	4.4988	0.3637
EFM-192A	CTRP2	6.9756	8.3863	4.5837	0.2063
MCF-7	CTRP2; CTRP1	7.1686	9.3153	4.3269	0.7101
HCC1806	CTRP2	7.1993	8.7473	4.5397	0.2153
JIMT-1	CTRP2	7.2366	8.5262	4.6306	0.0922
HCC38	CTRP2	7.2445	8.9801	4.4729	0.3151
CAMA-1	CTRP2	7.2749	13.18	2.6514	6.4508
MDA-MB-157	CTRP2	7.3044	9.3027	4.3769	0.485
BT-20	CTRP2	7.3805	8.7943	4.5899	0.1121
CAL-85-1	CTRP2	7.5561	9.7684	4.3058	0.5319
BT-549	CTRP2	7.6312	15.8609	1.6106	9.912
HCC1395	CTRP2	7.6782	9.3456	4.5067	0.1548
HCC1954	CTRP2	7.7164	9.1473	4.5876	0.0711
T-47D	CTRP2	7.781	13.7251	2.7173	5.5645
HCC1937	CTRP2	7.9184	9.6355	4.4929	0.13
CAL-51	CTRP2	7.9672	9.5233	4.5478	0.0755
AU565	CTRP2	8.359	21.1354	-0.434	15.7398
HCC1143	CTRP2	8.3842	10.5188	4.3555	0.2047
HCC2218	CTRP2	8.5876	23.5528	-1.4489	18.284
CAL-120	CTRP2	9.0364	28.5071	-3.5491	22.5687
MDA-MB-453	CTRP2	9.6137	22.5955	-0.2775	13.5289
HCC1428	CTRP2	12.2477	25.5855	-0.0255	9.7451
BT 416	CTRP2	1.7975	61.7766	-26.0709	46.1323
BT147	CTRP2	5.1635	20.9708	-2.8198	27.3054
BT 320	CTRP2	5.7846	7.2359	4.4868	1.242
BT164	CTRP2	6.0011	9.623	3.4951	4.8806
BT 145	CTRP2	6.0795	13.6524	1.5697	12.5084
BT 187	CTRP2	6.2242	8.3292	4.2498	1.6346
BT 112	CTRP2	6.2668	9.6328	3.6715	3.7938
BT 172	CTRP2	6.2706	14.3034	1.3928	12.8534
BT 248	CTRP2	6.3576	11.8424	2.6679	7.6978
BT 328	CTRP2	6.5371	14.7566	1.3692	12.4947
BT 422	CTRP2	6.5405	13.0351	2.2168	9.2163
BT 179	CTRP2	6.5486	14.844	1.3347	12.6045
BT 330	CTRP2	6.7329	7.8743	4.6744	0.1316
BT 359	CTRP2	6.775	11.695	3.0273	5.6541
BT 239	CTRP2	6.8076	8.3567	4.5274	0.3702
BT 482	CTRP2	6.9351	8.4939	4.5284	0.318
BT 286	CTRP2	6.9464	8.2443	4.6233	0.1542
BT 228	CTRP2	6.9572	8.7011	4.4594	0.4547
BT 139	CTRP2	6.9723	7.9884	4.7203	0.0473
BT 159	CTRP2	6.9867	8.1514	4.6702	0.0893
BT 333	CTRP2	7.3361	8.6777	4.6141	0.0942
BT 245	CTRP2	7.3433	9.2334	4.4189	0.3828
BT 231	CTRP2	7.5309	9.362	4.4459	0.2741
BT 131	CTRP2	7.9225	20.5757	-0.4729	16.5113
BT 498	CTRP2	8.3016	19.6692	0.2364	13.7267
BT 271	CTRP2	8.3455	28.0084	-3.816	24.0914
BT 428	CTRP2	8.4205	24.6817	-2.1225	20.2527
BT 216	CTRP2	9.2253	27.0447	-2.696	20.4539
BT 440	CTRP2	9.347	21.3677	0.1299	12.6268
BT 232	CTRP2	10.8992	23.3679	0.1804	10.5796
BT 504	CTRP2	11.0563	26.5688	-1.2147	14.3806
BT 224	CTRP2	12.8612	24.9344	0.6104	7.3364
BT 340	CTRP2	12.8634	32.3202	-2.7578	16.1009
BT 444	CTRP2	13.2602	39.7296	-6.0209	21.9428

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Tongue Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
YD-38	CTRP2	6.6939	7.7693	4.6968	0.1102

Cancer Drug Sensitivity Data Curated from 41 Cell Line(s) in Central Nervous System Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
SNU-466	CTRP2	6.0777	8.7524	3.9646	2.8887
SNU-489	CTRP2	6.2956	7.3378	4.6989	0.2183
KNS-81	CTRP2	6.5484	7.6668	4.6785	0.1722
SNU-1105	CTRP2	6.5512	7.8403	4.6157	0.2887
KG-1-C	CTRP2	6.5663	7.7836	4.6429	0.2294
KNS-60	CTRP2	6.6034	7.7934	4.654	0.1974
SNU-201	CTRP2	6.6357	7.9914	4.5937	0.3005
LN-18	CTRP2	6.6548	7.486	4.7795	0.0354
D283 Med	CTRP2	6.7986	12.3413	2.7341	6.7798
SW1088	CTRP2	6.9474	9.0795	4.3058	0.8511
Becker	CTRP2	6.9621	8.617	4.4934	0.3787
SNU-626	CTRP2	6.9684	8.1288	4.6715	0.0909
GB-1	CTRP2	6.9905	8.523	4.5398	0.277
8-MG-BA	CTRP2	7.0058	11.2078	3.4034	3.9026
ONS-76	CTRP2	7.0383	8.6211	4.5228	0.2922
M059K	CTRP2	7.0395	8.4507	4.585	0.1874
U-251MG	CTRP2	7.0708	8.6728	4.5168	0.2925
Hs 683	CTRP2	7.0987	8.3777	4.6325	0.1121
KNS-42	CTRP2	7.1112	8.5385	4.5808	0.176
YKG-1	CTRP2	7.126	8.3778	4.6422	0.097
SNU-738	CTRP2	7.1488	8.4444	4.6274	0.1092
GMS-10	CTRP2	7.2045	8.3887	4.666	0.0646
SF126	CTRP2	7.268	8.9224	4.5031	0.2551
U-87MG ATCC	CTRP2	7.2881	8.5629	4.6362	0.08
42-MG-BA	CTRP2	7.4942	9.0129	4.5554	0.1311
Daoy	CTRP2	7.5023	9.8841	4.2383	0.7118
SF295	CTRP2; CTRP1	7.5206	8.5174	4.7434	0.0133
YH-13	CTRP2	7.6402	8.8448	4.662	0.032
U-118MG	CTRP2	7.6619	9.007	4.6158	0.0563
SNB-75	CTRP2	7.7485	9.4652	4.4907	0.1609
KALS-1	CTRP2	8.0089	9.9321	4.423	0.1939
SF268	CTRP2	8.0635	10.478	4.248	0.4548
DK-MG	CTRP2	10.0055	21.1375	0.6607	10.1146
SF539	CTRP2	10.4966	21.0192	1.0135	8.4235
CCF-STTG1	CTRP2	11.7218	24.824	0.0097	10.1876
TM-31	CTRP2	11.9701	21.3683	1.6757	4.9809
LN-229	CTRP2; CTRP1	12.1121	22.0072	1.49	5.4631
GaMG	CTRP2; CTRP1	13.0538	23.9772	1.1385	5.7188
T98G	CTRP2	13.9535	28.944	-0.5513	9.5532
GOS-3	CTRP2	14.3989	29.1799	-0.4076	8.78
A-172	CTRP2	14.5227	35.2321	-3.0719	15.0689

Cancer Drug Sensitivity Data Curated from 22 Cell Line(s) in Endometrium Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
AN3-CA	CTRP2	5.259	6.5022	4.4857	1.9653
EN	CTRP2	5.5364	7.6283	4.136	2.9669
HEC-265	CTRP2; CTRP1	5.8713	8.2033	4.1013	2.698
JHUEM-1	CTRP2	6.3202	7.4221	4.6774	0.2527
HEC-251	CTRP2; CTRP1	6.4612	8.1635	4.4609	0.7817
HEC-6	CTRP2; CTRP1	6.5165	7.912	4.5875	0.4057
MFE-296	CTRP2	6.8522	8.9141	4.3279	0.8503
JHUEM-7	CTRP2	6.9005	8.427	4.5392	0.3095
RL95-2	CTRP2	7.0578	8.1578	4.6929	0.0592
KLE	CTRP2; CTRP1	7.0948	8.9141	4.4503	0.4522
HEC-59	CTRP2; CTRP1	7.1575	8.5464	4.6094	0.1494
HEC-151	CTRP2; CTRP1	7.1664	8.6124	4.5895	0.1746
EFE-184	CTRP2	7.2754	9.3166	4.3593	0.5367
HEC-108	CTRP2; CTRP1	7.3673	8.4099	4.7282	0.0243
HEC-50B	CTRP2	7.5342	9.3212	4.4618	0.2479
JHUEM-3	CTRP2	7.5384	9.3997	4.4352	0.2896
JHUEM-2	CTRP2; CTRP1	7.5616	9.4092	4.4548	0.2783
HEC-1-A	CTRP2	7.6064	9.9995	4.2388	0.6595
ESS-1	CTRP2	7.6792	17.3663	0.9172	12.3426
MFE-319	CTRP2; CTRP1	7.921	13.2981	3.0094	4.3935
HEC-1-B	CTRP2	8.0826	9.8991	4.4609	0.1379
Ishikawa (Heraklio) 02 ER-	CTRP2; CTRP1	6.223	12.736	2.142	10.0954

Cancer Drug Sensitivity Data Curated from 21 Cell Line(s) in Kidney Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
TUHR10TKB	CTRP2	6.1965	8.0436	4.3612	1.2675
RCC10RGB	CTRP2; CTRP1	6.7145	13.2527	2.2463	8.9024
TUHR4TKB	CTRP2	6.8145	8.0534	4.6415	0.1593
A-498	CTRP2	6.8837	8.092	4.6536	0.127
KMRC-2	CTRP2	6.9084	8.0386	4.681	0.0902
VMRC-RCZ	CTRP2	6.9159	9.4309	4.1445	1.3582
SNU-1272	CTRP2	6.963	8.4878	4.5419	0.2824
VMRC-RCW	CTRP2; CTRP1	7.1198	8.6621	4.5539	0.2416
UO-31	CTRP2	7.1811	11.7821	3.2459	4.2904
KMRC-3	CTRP2	7.288	9.7253	4.2044	0.9183
KMRC-20	CTRP2	7.2915	8.7968	4.5568	0.1686
TUHR14TKB	CTRP2	7.294	9.7585	4.1939	0.9434
Caki-2	CTRP2	7.3552	8.7565	4.5939	0.112
BFTC-909	CTRP2	7.3643	8.7239	4.6082	0.0959
KMRC-1	CTRP2	7.3865	9.0451	4.5044	0.221
ACHN	CTRP2	7.4534	9.0144	4.5401	0.1568
OS-RC-2	CTRP2	7.5615	9.8571	4.2743	0.599
CAL-54	CTRP2	7.6941	9.3228	4.5203	0.1365
769-P	CTRP2	7.7897	9.1171	4.6225	0.0425
786-O	CTRP2	7.8251	9.3062	4.5717	0.072
Caki-1	CTRP2	14.6139	45.3826	-7.8143	23.2568

Cancer Drug Sensitivity Data Curated from 53 Cell Line(s) in Large Intestine Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
SNU-C4	CTRP2; CTRP1	6.0556	7.7813	4.4112	1.2949
HCC-56	CTRP2	6.0945	7.8405	4.3941	1.2518
LS1034	CTRP2	6.5095	8.4052	4.3708	0.9661
DLD-1	CTRP2; CTRP1	6.5099	7.4369	4.7597	0.0887
C2BBe1	CTRP2; CTRP1	6.5173	9.2766	4.0058	2.2765
OUMS-23	CTRP2	6.522	7.5304	4.7172	0.1198
SNU-61	CTRP2; CTRP1	6.539	9.2633	4.0245	2.1846
RKO	CTRP2; CTRP1	6.5509	8.2061	4.4865	0.6481
SW1417	CTRP2	6.5606	8.7262	4.2607	1.2773
KM12	CTRP2; CTRP1	6.5695	8.1224	4.5285	0.5245
SW48	CTRP2; CTRP1	6.6958	8.6159	4.3885	0.8313
LS411N	CTRP2; CTRP1	6.6969	8.1115	4.5878	0.324
MDST8	CTRP2; CTRP1	6.7075	7.9938	4.6359	0.2264
CCK-81	CTRP2	6.7209	9.3532	4.0747	1.76
T84	CTRP2	6.7259	8.8304	4.3011	1.0172
SW1116	CTRP2	6.7786	8.3811	4.5058	0.431
SW948	CTRP2; CTRP1	6.8024	7.8663	4.7167	0.0868
COLO205	CTRP2; CTRP1	6.8048	7.9865	4.6757	0.1366
CL-40	CTRP1	6.8108	8.7692	4.3808	1.6683
HCT 116	CTRP2; CTRP1	6.8837	8.2902	4.5969	0.2394
HT-29	CTRP2; CTRP1	7.0035	8.8038	4.4536	0.4858
LS123	CTRP2; CTRP1	7.0406	9.2661	4.2876	0.8913
SNU-503	CTRP2	7.056	8.9548	4.4042	0.5357
CL-34	CTRP1	7.0916	9.0409	4.4002	1.2207
SNU-C1	CTRP2	7.1353	8.6544	4.5486	0.2185
NCI-H747	CTRP2	7.1517	9.7605	4.1248	1.2387
CW-2	CTRP2; CTRP1	7.1536	10.3647	3.8813	2.0805
NCI-H716	CTRP2	7.1546	8.9006	4.4661	0.3595
COLO201	CTRP2	7.1889	8.4133	4.6522	0.0783
HCT 8	CTRP2; CTRP1	7.1935	8.1361	4.76	0.0196
SNU-175	CTRP1	7.2001	9.295	4.3489	1.3694
HT-55	CTRP2; CTRP1	7.2405	9.0135	4.473	0.3481
SW480	CTRP1	7.2406	9.5934	4.2491	1.8714
HT115	CTRP2; CTRP1	7.2687	8.5695	4.6415	0.0932
GP2d	CTRP2; CTRP1	7.3355	8.9805	4.5223	0.2326
RCM-1 [Human ESC]	CTRP2; CTRP1	7.4008	8.7543	4.6251	0.0905
HCT 15	CTRP2	7.425	8.9587	4.5491	0.1511
COLO 678	CTRP2; CTRP1	7.4599	9.0096	4.5584	0.1534
SK-CO-1	CTRP2; CTRP1	7.4626	8.9216	4.5898	0.1168
SNU-C5	CTRP2; CTRP1	7.4733	9.5885	4.3532	0.5016
LS513	CTRP2; CTRP1	7.4778	8.774	4.6451	0.0645
SW620	CTRP2; CTRP1	7.5224	8.9569	4.5989	0.0987
SNU-81	CTRP2; CTRP1	7.6488	9.1503	4.5776	0.1016
SNU-407	CTRP2	7.6835	9.3905	4.493	0.1704
CL-11	CTRP2	7.6879	9.494	4.4583	0.2154
COLO 320	CTRP2; CTRP1	7.7268	10.5198	4.1022	0.9784
SNU-1033	CTRP2	7.7725	9.519	4.4807	0.1684
LS180	CTRP2; CTRP1	7.7756	9.1437	4.6233	0.0525
NCI-H508	CTRP2; CTRP1	8.0644	9.5576	4.5838	0.054
LoVo	CTRP2; CTRP1	8.2237	10.0909	4.4596	0.1349
SNU-C2A	CTRP2; CTRP1	8.6656	10.4773	4.4822	0.0687
SNU-1040	CTRP1	8.8505	31.9146	-5.3549	33.4364
SW403	CTRP1	9.0217	14.3318	3.16	5.754

Cancer Drug Sensitivity Data Curated from 22 Cell Line(s) in Liver Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
SNU-886	CTRP2	0.2515	2.8237	-3.7925	1.0514
SNU-878	CTRP2	6.0301	7.8397	4.3577	1.4485
HuH-6	CTRP2	6.3705	8.719	4.1592	1.8088
JHH-6	CTRP2; CTRP1	6.4507	7.2932	4.7881	0.0668
SNU-182	CTRP2	6.4643	9.2463	3.9757	2.3788
Hep-G2	CTRP2; CTRP1	6.7713	8.1636	4.5988	0.2737
JHH-1	CTRP2	6.8329	7.772	4.7449	0.043
JHH-4	CTRP2	6.8796	8.8617	4.362	0.7386
PLC/PRF/5	CTRP2	6.9861	12.7894	2.6461	6.863
JHH-2	CTRP2	7.0006	8.7268	4.4679	0.4169
HLF	CTRP2	7.2729	9.1982	4.4032	0.4418
Hep 3B2.1-7	CTRP2	7.2918	8.7924	4.5584	0.1663
SNU-387	CTRP2	7.3648	9.1918	4.4429	0.33
SNU-423	CTRP2	7.4215	9.1351	4.4855	0.2409
JHH-5	CTRP2	7.4857	9.4489	4.3965	0.3753
SNU-398	CTRP2; CTRP1	7.942	9.7057	4.4915	0.1452
Li-7	CTRP2	7.9755	9.8238	4.4485	0.1693
SNU-761	CTRP2	9.8192	21.3034	0.4662	10.962
SK-HEP-1	CTRP2	10.079	17.9691	2.1386	5.1736
HuH-1	CTRP2	10.9573	25.9332	-0.9792	13.8616
SNU-449	CTRP2; CTRP1	11.4267	20.3828	1.8272	5.0217
SNU-475	CTRP2	11.7924	35.1389	-4.8179	21.5084

Cancer Drug Sensitivity Data Curated from 154 Cell Line(s) in Lung Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
HCC33	CTRP1	5.6561	7.1595	4.4548	3.4115
NCI-H526	CTRP2	5.8659	7.6851	4.3297	1.7396
NCI-H1930	CTRP1	5.8863	9.2229	3.6197	9.7962
SCLC-21H	CTRP1	5.9914	7.3714	4.5562	1.8321
NCI-H1836	CTRP1	6.0402	8.0988	4.2581	4.0222
BEN	CTRP2; CTRP1	6.1068	7.5633	4.5345	0.8258
Calu-1	CTRP2	6.1657	9.3139	3.7563	3.5941
NCI-H2081	CTRP2; CTRP1	6.2158	8.2298	4.3022	1.5207
MOR/CPR	CTRP2	6.2589	7.3494	4.6794	0.2744
NCI-H810	CTRP2; CTRP1	6.2901	7.8823	4.4932	0.8099
NCI-H1915	CTRP2; CTRP1	6.326	9.1283	3.9582	2.674
NCI-H2029	CTRP2; CTRP1	6.3273	7.6795	4.5943	0.4909
A-549	CTRP2; CTRP1	6.376	12.9426	2.1536	9.7995
NCI-H196	CTRP2	6.376	8.2137	4.3836	1.0321
SBC-5	CTRP2	6.3857	7.5124	4.6706	0.241
COR-L95	CTRP2	6.4387	8.8908	4.1213	1.8743
NCI-H2122	CTRP2; CTRP1	6.44	8.2284	4.4233	0.9117
NCI-H2444	CTRP2	6.4517	7.4433	4.7217	0.1301
LK2	CTRP2	6.4906	7.1539	4.8339	0.0166
COLO 668	CTRP2; CTRP1	6.5495	9.4447	3.9485	2.4521
NCI-H1573	CTRP2; CTRP1	6.5636	10.5676	3.4349	4.4039
LC-1/sq-SF	CTRP2; CTRP1	6.5991	11.5647	2.9829	6.1472
NCI-H1563	CTRP2	6.6145	13.8764	1.8587	10.502
DMS 53	CTRP2	6.6179	16.4953	0.5715	15.2346
DMS 114	CTRP2	6.6322	8.4949	4.3941	0.8072
NCI-H226	CTRP2	6.6365	7.8694	4.6393	0.2128
NCI-H1105	CTRP2; CTRP1	6.6453	9.8119	3.8382	2.7543
NCI-H2141	CTRP2; CTRP1	6.6618	8.1871	4.5441	0.4376
NCI-H2126	CTRP2; CTRP1	6.6723	7.9237	4.6476	0.2167
HCC78	CTRP2; CTRP1	6.6828	10.2844	3.6436	3.4445
HCC2108	CTRP1	6.6907	8.5195	4.4253	1.5657
HARA [Human squamous cell lung carcinoma]	CTRP2; CTRP1	6.7285	9.1064	4.1988	1.3957
NCI-H82	CTRP1	6.7347	12.4475	2.6508	14.3734
SK-MES-1	CTRP2	6.7399	10.8827	3.3883	4.2865
NCI-H522	CTRP2; CTRP1	6.7442	9.4931	4.0388	1.9245
NCI-H23	CTRP2; CTRP1	6.7483	9.7265	3.9373	2.2799
PC-14	CTRP2	6.7578	8.548	4.4314	0.6252
LUDLU-1	CTRP2	6.7979	8.9579	4.2837	1.0171
NCI-H1876	CTRP1	6.8161	8.3732	4.5386	0.8146
NCI-H460	CTRP2; CTRP1	6.8242	7.9511	4.6952	0.1075
IA-LM	CTRP2	6.8318	8.3279	4.5482	0.3172
NCI-H1341	CTRP2	6.8334	8.4976	4.4845	0.4544
COR-L279	CTRP1	6.8632	8.6924	4.4355	1.2887
NCI-H211	CTRP2	6.8693	11.0389	3.3971	4.0907
RERF-LC-KJ	CTRP1	6.8737	12.2535	2.8385	12.6875
NCI-H1339	CTRP2	6.8939	8.4059	4.5444	0.3018
EPLC-272H	CTRP2; CTRP1	6.8957	11.2907	3.3084	4.469
NCI-H1568	CTRP2; CTRP1	6.9008	9.2985	4.206	1.2323
LCLC-103H	CTRP2; CTRP1	6.9381	7.9863	4.7236	0.0612
NCI-H889	CTRP2	6.9383	8.651	4.4705	0.4382
HCC366	CTRP2	6.9594	9.3159	4.2146	1.1078
COR-L23	CTRP1	6.9596	8.1789	4.6653	0.2539
HOP-62	CTRP2	7.0424	12.7971	2.68	6.6525
SHP-77	CTRP2; CTRP1	7.05	8.2024	4.6895	0.0775
NCI-H1048	CTRP1	7.0511	10.9929	3.5419	7.1265
HCC44	CTRP2; CTRP1	7.0585	8.7341	4.5031	0.356
HCC95	CTRP2	7.0586	8.5629	4.552	0.2346
COR-L51	CTRP2; CTRP1	7.0651	22.5154	-2.059	22.2592
CAL-12T	CTRP1	7.068	10.4008	3.8181	5.0528
HCC1359	CTRP1	7.0923	14.568	1.8739	18.0023
NCI-H1395	CTRP2	7.1103	28.4225	-4.9707	28.0215
NCI-H2286	CTRP2; CTRP1	7.123	14.6091	1.8754	9.7239
NCI-H2085	CTRP2	7.1236	9.0858	4.3829	0.5533
NCI-H2342	CTRP2; CTRP1	7.1271	20.3329	-0.9305	19.1714
NCI-H1092	CTRP2	7.1368	9.0099	4.4176	0.4682
HCC1588	CTRP2	7.1649	8.4648	4.6262	0.1079
NCI-H2170	CTRP2	7.2216	11.3902	3.4499	3.4827
NCI-H3255	CTRP1	7.2417	8.7832	4.5571	0.4367
NCI-H2196	CTRP2	7.2535	8.7215	4.5692	0.1602
NCI-H1963	CTRP1	7.254	9.4328	4.3188	1.4681
LOU-NH91	CTRP2	7.2639	8.8335	4.5334	0.2083
NCI-H1975	CTRP1	7.271	8.8873	4.531	0.5069
Calu-3	CTRP2; CTRP1	7.2732	9.0054	4.489	0.3071
NCI-H1944	CTRP2; CTRP1	7.2929	13.6668	2.4441	7.2955
NCI-H1781	CTRP1	7.2985	8.7164	4.6016	0.2823
NCI-H1792	CTRP2; CTRP1	7.3513	12.5908	2.9888	5.128
DV-90	CTRP2; CTRP1	7.3615	9.2049	4.4508	0.3478
Lu-99	CTRP2; CTRP1	7.3809	8.456	4.7176	0.0282
NCI-H1755	CTRP2; CTRP1	7.3945	9.2077	4.4629	0.3148
DMS 454	CTRP2	7.4187	10.2125	4.0684	1.2173
NCI-H1155	CTRP2	7.4256	8.6951	4.6392	0.062
HCC1195	CTRP2; CTRP1	7.4257	8.6935	4.6542	0.063
NCI-H841	CTRP2; CTRP1	7.438	8.8665	4.5999	0.11
NCI-H2030	CTRP2; CTRP1	7.4577	9.7147	4.2984	0.6315
HOP-92	CTRP2	7.4704	9.5597	4.3489	0.4757
NCI-H2106	CTRP2	7.4758	9.2232	4.4747	0.2434
NCI-H1651	CTRP2	7.48	9.5507	4.3563	0.4566
NCI-H2009	CTRP2; CTRP1	7.4863	8.9867	4.5759	0.1281
RERF-LC-MS	CTRP2	7.5009	9.2394	4.4784	0.2312
NCI-H650	CTRP2; CTRP1	7.5027	8.8112	4.6412	0.0649
NCI-H2405	CTRP2; CTRP1	7.5086	11.4853	3.5845	2.7673
HCC827	CTRP2; CTRP1	7.5124	9.4901	4.406	0.38
NCI-H2228	CTRP2	7.529	11.1442	3.7316	2.1874
LCLC-97TM1	CTRP2; CTRP1	7.5345	9.0841	4.5596	0.1383
VMRC-LCD	CTRP2; CTRP1	7.5563	9.1996	4.5274	0.1734
NCI-H1838	CTRP2	7.5897	9.4326	4.4431	0.2625
HCC15	CTRP2; CTRP1	7.5959	9.736	4.3484	0.4624
Sq-1	CTRP2; CTRP1	7.6014	8.8052	4.6765	0.035
NCI-H838	CTRP2	7.616	8.9573	4.6168	0.0598
T3M-10	CTRP2; CTRP1	7.6195	9.4579	4.4596	0.255
NCI-H69	CTRP2	7.628	9.5246	4.4247	0.2813
NCI-H1581	CTRP2	7.6343	9.0704	4.5852	0.082
NCI-H2087	CTRP2	7.656	9.6492	4.3905	0.3304
NCI-H1435	CTRP2; CTRP1	7.6705	9.081	4.6085	0.0725
HCC4006	CTRP2; CTRP1	7.6716	9.0544	4.6177	0.0654
NCI-H1650	CTRP2	7.6899	9.3753	4.5006	0.1599
NCI-H520	CTRP2	7.7058	9.5936	4.4297	0.2528
NCI-H322	CTRP2	7.7422	9.0497	4.6287	0.0424
NCI-H727	CTRP2; CTRP1	7.7474	9.5942	4.4593	0.2238
NCI-H661	CTRP2; CTRP1	7.7531	9.5298	4.4841	0.1889
NCI-H1623	CTRP2	7.7602	9.4412	4.5032	0.1444
NCI-H2291	CTRP2	7.7636	9.6732	4.4232	0.248
NCI-H2172	CTRP2; CTRP1	7.7698	8.8819	4.7069	0.0159
HCC2935	CTRP2; CTRP1	7.8134	9.3739	4.5593	0.0968
COLO 699	CTRP2; CTRP1	7.8292	9.5493	4.505	0.1492
NCI-H1793	CTRP2; CTRP1	7.837	9.6781	4.463	0.199
COR-L88	CTRP2; CTRP1	7.8423	33.7507	-7.0385	30.0202
NCI-H1703	CTRP2	7.8486	9.4	4.5484	0.0878
NCI-H1373	CTRP2; CTRP1	7.8537	9.6173	4.4903	0.1618
NCI-H1869	CTRP2	7.8609	9.4653	4.5306	0.1017
EBC-1	CTRP2; CTRP1	7.8915	20.2078	-0.3042	16.1001
NCI-H1184	CTRP2	7.8989	9.6743	4.4726	0.1551
Calu-6	CTRP2; CTRP1	7.9156	9.4224	4.5783	0.0703
HCC1171	CTRP2	7.9268	9.8459	4.423	0.2108
NCI-H358	CTRP1	7.9622	9.7455	4.485	0.3196
NCI-H441	CTRP2; CTRP1	7.9799	9.55	4.5576	0.0791
NCI-H1299	CTRP2; CTRP1	7.9971	9.7091	4.5099	0.1181
LXF 289	CTRP2; CTRP1	8.0004	9.7172	4.5083	0.1192
HCC2279	CTRP2	8.088	10.014	4.4233	0.1785
NCI-H1694	CTRP2; CTRP1	8.1986	15.0921	2.3548	6.4735
NCI-H2110	CTRP2; CTRP1	8.208	9.9206	4.5118	0.0905
HCC1833	CTRP2; CTRP1	8.2665	10.0726	4.4809	0.1094
NCI-H1355	CTRP2; CTRP1	8.3797	10.3152	4.4382	0.1336
NCI-H446	CTRP2	8.4671	18.7574	0.7879	11.6604
NCI-H1693	CTRP2	8.6914	32.999	-6.0221	27.4138
NCI-H596	CTRP1	8.7229	17.4503	1.5856	15.2473
NCI-H1437	CTRP1	8.7922	28.3978	-3.6642	30.9821
SW1271	CTRP2	9.3591	32.2284	-5.1408	25.1067
KNS-62	CTRP2; CTRP1	9.4253	15.8294	2.7298	3.889
NCI-H2023	CTRP2; CTRP1	9.5589	26.1805	-2.0273	18.4449
NCI-H2073	CTRP1	9.6691	35.5582	-6.5399	33.5484
SK-LU-1	CTRP2; CTRP1	9.697	19.6092	1.1897	8.7994
NCI-H647	CTRP2	9.8362	23.5643	-0.591	14.1647
DMS 273	CTRP2; CTRP1	9.9696	19.2594	1.5135	7.4125
EKVX	CTRP2	10.0767	25.2158	-1.2184	15.612
Lu-65	CTRP2; CTRP1	10.1211	22.157	0.2704	11.2656
RERF-LC-A1	CTRP2	10.4467	22.7019	0.209	11.0136
COR-L105	CTRP2	10.5836	27.3051	-1.8767	16.6805
NCI-H1666	CTRP2; CTRP1	11.1329	38.1903	-6.7579	25.4813
NCI-H292	CTRP2	11.277	24.5028	-0.1116	11.0258
HCC1438	CTRP2	12.3784	25.0739	0.2797	8.7365
ChaGo-K-1	CTRP2; CTRP1	14.3593	31.531	-1.4648	11.5511
RERF-LC-Ad2	CTRP2	15.7502	40.7385	-4.865	17.4436
Hs 888.Lu	CTRP2	6.4681	8.5273	4.2974	1.236

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Clivus Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
U-CH1	CTRP2	2.7234	30.6195	-9.7254	40.2038

Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Thigh Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
H-STS	CTRP2	6.0606	7.0267	4.7184	0.2769
SYO-1	CTRP2	6.9697	8.4523	4.5575	0.252
P-STS	CTRP2	7.0078	15.6237	1.2884	12.0354

Cancer Drug Sensitivity Data Curated from 45 Cell Line(s) in Ovary Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
2004	CTRP2	6.6695	9.7145	3.8843	2.49
JHOS-2	CTRP2	3.9591	5.94	3.5354	8.8062
TOV-112D	CTRP2	5.953	8.2191	4.1353	2.3822
COV318	CTRP1	6.3768	7.6389	4.6325	0.788
OV56	CTRP2	6.3925	7.4674	4.69	0.2009
OVKATE	CTRP1	6.3933	8.7306	4.1797	3.8073
OVK18	CTRP2; CTRP1	6.63	8.3001	4.4854	0.603
OVMANA	CTRP1	6.6382	8.5553	4.3855	1.888
JHOM-1	CTRP2; CTRP1	6.6688	8.3395	4.4874	0.5751
DOV13	CTRP2	6.8145	8.5163	4.4691	0.5
ES2	CTRP2	6.8876	7.9872	4.6912	0.0828
RMG-I	CTRP2; CTRP1	6.8982	10.5333	3.6602	3.1313
OAW42	CTRP2; CTRP1	6.9545	8.091	4.6937	0.0871
OVISE	CTRP2	7.0139	8.3135	4.6239	0.1386
Kuramochi	CTRP2	7.0177	11.1265	3.4481	3.7201
ONCO-DG-1	CTRP2	7.0278	8.4327	4.587	0.1873
IGROV-1	CTRP2; CTRP1	7.0743	8.8182	4.478	0.4012
SK-OV-3	CTRP2; CTRP1	7.158	10.6182	3.7723	2.4528
TOV-21G	CTRP2	7.1605	8.5213	4.605	0.1332
SNU-119	CTRP2	7.1746	9.1316	4.3872	0.5194
SNU-8	CTRP2	7.1791	8.2358	4.7082	0.0376
TYK-nu	CTRP2; CTRP1	7.1842	8.6954	4.5667	0.2036
OV7	CTRP2; CTRP1	7.1928	9.9086	4.0968	1.3469
JHOS-4	CTRP1	7.1963	14.0949	2.1742	15.9925
HEY A8	CTRP2; CTRP1	7.2706	8.6405	4.6178	0.1178
OVCAR-8	CTRP2; CTRP1	7.279	9.1913	4.4223	0.4351
COV362	CTRP2; CTRP1	7.2902	8.8384	4.5558	0.1936
COV434	CTRP2; CTRP1	7.3086	11.8056	3.3249	3.9138
OC 314	CTRP2	7.3102	8.5448	4.65	0.0658
OVCAR-4	CTRP2; CTRP1	7.4545	9.3293	4.4421	0.3328
OVTOKO	CTRP2	7.4721	9.3089	4.4424	0.2971
EFO-21	CTRP2; CTRP1	7.5229	8.7673	4.6627	0.0483
MCAS	CTRP2	7.594	9.3581	4.4713	0.2189
OV-90	CTRP2; CTRP1	7.6168	9.0726	4.5927	0.0919
FU-OV-1	CTRP2	7.6184	9.423	4.4574	0.2332
JHOC-5	CTRP2; CTRP1	7.653	8.9381	4.65	0.0459
EFO-27	CTRP2; CTRP1	7.8006	9.9845	4.3389	0.4066
A2780	CTRP2; CTRP1	7.8289	9.3322	4.5787	0.0787
OAW28	CTRP2	7.8854	10.2511	4.2603	0.495
OVSAHO	CTRP2	8.0881	9.5575	4.5773	0.0468
RMUG-S	CTRP1	10.1065	22.2849	0.2013	18.2376
OVCAR-5	CTRP2	11.9042	35.6608	-4.9926	21.6937
Caov-3	CTRP2; CTRP1	14.8947	36.9946	-3.646	15.9451
COV644	CTRP2; CTRP1	15.7218	38.8647	-4.0002	15.8636
SNU-840	CTRP2; CTRP1	16.6917	73.0536	-19.7982	32.272

Cancer Drug Sensitivity Data Curated from 21 Cell Line(s) in Soft Tissue Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
Yamato-SS	CTRP2	6.6906	7.8594	4.6638	0.157
Aska-SS	CTRP2	7.0833	16.6296	0.8507	13.4946
TE 441.T	CTRP2	5.7963	7.1092	4.5509	0.9953
BT-16	CTRP2	5.9842	7.488	4.4884	1.0296
Rh41	CTRP2	6.0481	8.0119	4.2902	1.6769
BT-12	CTRP2	6.0614	6.9223	4.7585	0.1878
KYM-1	CTRP2	6.6896	8.3669	4.4723	0.5576
SW982	CTRP2	6.7232	8.0051	4.6238	0.2129
A-204	CTRP2	6.7511	9.253	4.1345	1.5296
Tm87-16	CTRP2	7.0492	8.9087	4.4191	0.5044
TTC-709	CTRP2	7.2217	9.0052	4.4545	0.3578
HT-1080	CTRP2; CTRP1	7.5532	8.9568	4.6097	0.0848
TE 617.T	CTRP2	7.5746	8.8333	4.6439	0.0458
RKN	CTRP2; CTRP1	7.6037	9.0751	4.5873	0.0986
GCT	CTRP2	7.6977	9.1195	4.5905	0.0708
Hs 729.T	CTRP2	8.069	9.3999	4.6225	0.0273
G-402	CTRP2	8.0727	10.354	4.297	0.3645
G-401	CTRP2; CTRP1	9.3771	17.3358	2.0364	6.2757
RD	CTRP2	11.0545	21.6345	1.061	7.6897
SK-LMS-1	CTRP2	13.2951	27.5531	-0.305	9.5031
SK-UT-1	CTRP2	15.0457	29.6449	-0.2604	7.8591

Cancer Drug Sensitivity Data Curated from 8 Cell Line(s) in Pleura Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
MSTO-211H	CTRP2; CTRP1	6.9177	11.8297	3.069	5.3703
ACC-MESO-1	CTRP2	7.0708	8.6396	4.5289	0.2705
MPP 89	CTRP2	7.1408	8.8272	4.4878	0.3226
NCI-H28	CTRP2; CTRP1	7.1791	9.4069	4.2953	0.7862
NCI-H2052	CTRP2; CTRP1	7.7863	9.364	4.5532	0.1059
NCI-H2452	CTRP2	10.2515	28.0768	-2.4741	18.558
IST-Mes1	CTRP2	10.6828	25.5948	-0.9974	14.2443
JL-1	CTRP2	12.4698	21.835	1.7322	4.4364

Cancer Drug Sensitivity Data Curated from 5 Cell Line(s) in Prostate Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
VCaP	CTRP2	5.7901	8.0978	4.0855	2.7982
LNCaP clone FGC	CTRP2	7.0875	9.6353	4.1451	1.2241
DU145	CTRP2	7.4984	9.281	4.4626	0.2563
22Rv1	CTRP2	7.9202	9.754	4.4527	0.1745
PaCa-3	CTRP2; CTRP1	15.3747	28.4376	0.4356	5.8739

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Salivary Gland Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
YD-15	CTRP2	6.1382	11.2998	2.7748	7.6085

Cancer Drug Sensitivity Data Curated from 33 Cell Line(s) in Stomach Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
SNU-16	CTRP2	5.738	6.8971	4.6123	0.8359
SNU-216	CTRP2	5.8681	27.7328	-5.6209	30.975
GSU	CTRP2	5.9259	6.5362	4.8461	0.0759
SH-10-TC	CTRP2; CTRP1	6.1571	8.4474	4.1689	2.0751
MKN45	CTRP2	6.3139	7.3435	4.7042	0.2013
NUGC-4	CTRP2; CTRP1	6.4218	9.3253	3.9262	2.6817
23132/87	CTRP2	6.7014	8.0199	4.6098	0.2451
SNU-1	CTRP2	6.741	12.4985	2.619	7.3186
Fu97	CTRP2; CTRP1	6.7818	8.2807	4.5593	0.3494
OCUM-1	CTRP2	6.9299	16.3943	0.8539	13.7298
SNU-620	CTRP2	6.9423	8.1987	4.6378	0.1354
ECC12	CTRP2	6.9556	7.8669	4.7548	0.0274
GSS	CTRP2	6.9702	8.3479	4.5954	0.1893
SNU-668	CTRP2	6.9981	8.7263	4.4671	0.4198
HuG1-N	CTRP2	7.0255	9.2016	4.2931	0.8373
Hs 746.T	CTRP2	7.0733	8.6351	4.5315	0.2652
HGC-27	CTRP2	7.3209	8.8849	4.5366	0.1898
ECC10	CTRP2	7.3366	9.0297	4.4908	0.2557
IM95	CTRP2	7.382	8.9806	4.5256	0.1912
SNU-601	CTRP2	7.3842	8.7868	4.5938	0.1075
NUGC-3	CTRP2	7.424	8.9283	4.5593	0.139
AGS	CTRP2; CTRP1	7.4673	8.7945	4.6346	0.0739
LMSU	CTRP2	7.5454	9.3446	4.4577	0.2514
MKN1	CTRP2	7.5964	9.1511	4.5444	0.1262
SNU-719	CTRP2	7.7365	9.3817	4.5152	0.1351
KATO III	CTRP2	7.7661	9.4954	4.4865	0.1626
MKN74	CTRP2; CTRP1	7.8369	9.8381	4.4063	0.2805
SNU-5	CTRP2	8.4137	18.9077	0.6799	12.1001
MKN7	CTRP2; CTRP1	9.1587	16.5662	2.2562	5.7476
KE-39	CTRP2	9.2653	11.3712	4.3742	0.0776
SNU-685	CTRP2	6.9502	8.2652	4.6173	0.1617
SNG-M	CTRP2; CTRP1	7.886	9.3371	4.5965	0.0604
SNU-1077	CTRP2	8.0345	9.585	4.5502	0.0674

Cancer Drug Sensitivity Data Curated from 11 Cell Line(s) in Thyroid Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
B-CPAP	CTRP2	6.6031	8.0009	4.5766	0.3507
SW579	CTRP2	6.6535	7.8889	4.6388	0.2082
FTC-133	CTRP2	6.958	8.2556	4.6236	0.1511
ML-1 [Human leukemia]	CTRP2	6.973	8.8227	4.4194	0.5404
8505C	CTRP2	7.0232	10.6811	3.6544	2.9492
8305C	CTRP2	7.0235	8.6761	4.4964	0.3483
CGTH-W-1	CTRP2	7.071	8.3251	4.6407	0.1076
TT	CTRP2	7.2661	8.6354	4.6037	0.1158
BHT-101	CTRP2	7.3563	8.807	4.5769	0.1307
FTC-238	CTRP2	10.2498	19.2981	1.6459	6.6247
TT2609-C02	CTRP2	11.7946	33.9002	-4.2192	20.3808

Cancer Drug Sensitivity Data Curated from 27 Cell Line(s) in Upper Aerodigestive Tract Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
YD-10B	CTRP2	3.6536	22.1199	-4.6783	33.5287
BICR 6	CTRP2	6.765	15.5758	1.1347	12.9875
SNU-1066	CTRP2	6.89	9.2673	4.2004	1.203
BICR 18	CTRP2	6.9075	8.8676	4.3725	0.694
HSC-2	CTRP2; CTRP1	6.9099	8.2467	4.6228	0.1888
CAL-33	CTRP2	6.9214	9.9912	3.9047	2.1579
PE/CA-PJ49	CTRP2	6.9341	8.0394	4.6899	0.0774
CAL-27	CTRP2	6.9955	8.2672	4.6334	0.1302
SNU-1076	CTRP2	7.0693	8.1062	4.7141	0.0428
SNU-1214	CTRP2	7.1362	9.0038	4.4197	0.4638
BICR 16	CTRP2	7.143	9.4489	4.2482	0.8877
HSC-3	CTRP2	7.1468	8.3581	4.6562	0.0802
BICR 22	CTRP2	7.1471	8.4974	4.6085	0.1316
SCC-4	CTRP2	7.1518	8.4634	4.6219	0.1148
BHY	CTRP2	7.4444	8.7368	4.6317	0.0657
PE/CA-PJ34 (clone C12)	CTRP2	7.4617	8.7311	4.6396	0.0582
SNU-899	CTRP2	7.4637	9.0061	4.5468	0.1466
SCC-9	CTRP2; CTRP1	7.6723	9.845	4.3389	0.4524
PE/CA-PJ15	CTRP2	7.6862	9.1098	4.5898	0.0726
BICR 56	CTRP2	7.6875	9.016	4.6215	0.0506
HSC-4	CTRP2	7.9948	16.4185	1.5884	9.487
BICR 31	CTRP2	8.9638	17.2982	1.7941	7.5214
FaDu	CTRP2	9.1324	17.623	1.7474	7.489
YD-8	CTRP2	10.0977	21.9106	0.3586	10.9641
SNU-46	CTRP2	11.2915	35.4282	-5.3085	22.9657
SNU-1041	CTRP2	13.3347	41.1915	-6.6736	22.8915
PE/CA-PJ41 (clone D2)	CTRP2	13.4054	28.1246	-0.4974	9.9199

Cancer Drug Sensitivity Data Curated from 23 Cell Line(s) in Urinary Tract Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
JMSU-1	CTRP2	2.3655	12.9178	-1.2994	29.9648
BC-3C	CTRP2	6.1492	13.1671	1.863	11.2493
BFTC-905	CTRP2	6.5396	7.8282	4.6154	0.2938
639V	CTRP2	6.6833	7.6934	4.7193	0.0854
RT-112	CTRP2	6.7249	8.6032	4.394	0.7463
253J	CTRP2	6.8186	8.0067	4.6595	0.1329
TCCSUP	CTRP2	6.9272	8.7373	4.4325	0.5316
647V	CTRP2	7.0281	8.7935	4.4542	0.4351
CAL-29	CTRP2	7.1359	8.4474	4.6217	0.1179
HT-1197	CTRP2	7.1538	8.5374	4.597	0.1447
253J-BV	CTRP2	7.1665	8.7042	4.5426	0.2195
HT-1376	CTRP2; CTRP1	7.2116	9.553	4.2519	0.8833
RT-4	CTRP2; CTRP1	7.273	9.1462	4.4368	0.4077
UM-UC-1	CTRP2	7.3281	8.9809	4.5051	0.2351
5637	CTRP2; CTRP1	7.4071	9.6381	4.306	0.6379
SW1710	CTRP2	7.4694	9.1742	4.4897	0.2222
SCaBER	CTRP2	7.47	16.0605	1.4034	10.9086
UM-UC-3	CTRP2; CTRP1	7.5339	11.1895	3.7276	2.2552
KMBC-2	CTRP2; CTRP1	7.6683	10.1691	4.2139	0.7289
VM-CUB-1	CTRP2	9.4694	18.9119	1.3596	8.4334
U-BLC1	CTRP2	11.2006	24.6079	-0.2071	11.3907
J82	CTRP2	13.775	30.9985	-1.5805	12.3594
T24	CTRP2	14.946	30.6	-0.7303	9.1413

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Urogenital System Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
HeLa	CTRP2	6.5493	7.5863	4.7076	0.127

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Dexamethasone

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Salsalate	DM13P4C	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Dexamethasone and Salsalate.	Rheumatoid arthritis [FA20]	[20]
Canakinumab	DM8HLO5	Moderate	Additive immunosuppressive effects by the combination of Dexamethasone and Canakinumab.	Rheumatoid arthritis [FA20]	[21]
Rilonacept	DMGLUQS	Moderate	Additive immunosuppressive effects by the combination of Dexamethasone and Rilonacept.	Rheumatoid arthritis [FA20]	[21]
Golimumab	DMHZV7X	Major	Additive immunosuppressive effects by the combination of Dexamethasone and Golimumab.	Rheumatoid arthritis [FA20]	[22]

Coadministration of a Drug Treating the Disease Different from Dexamethasone (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Sodium bicarbonate	DMMU6BJ	Minor	Decreased absorption of Dexamethasone due to altered gastric pH caused by Sodium bicarbonate.	Acidosis [5C73]	[23]
Midostaurin	DMI6E0R	Moderate	Increased metabolism of Dexamethasone caused by Midostaurin mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[24]
Oliceridine	DM6MDCF	Major	Increased metabolism of Dexamethasone caused by Oliceridine mediated induction of CYP450 enzyme.	Acute pain [MG31]	[25]
Ivabradine	DM0L594	Moderate	Increased metabolism of Dexamethasone caused by Ivabradine mediated induction of CYP450 enzyme.	Angina pectoris [BA40]	[26]
Dronedarone	DMA8FS5	Moderate	Increased metabolism of Dexamethasone caused by Dronedarone mediated induction of CYP450 enzyme.	Angina pectoris [BA40]	[27]
Bedaquiline	DM3906J	Major	Increased metabolism of Dexamethasone caused by Bedaquiline mediated induction of CYP450 enzyme.	Antimicrobial drug resistance [MG50-MG52]	[26]
Posaconazole	DMUL5EW	Moderate	Decreased metabolism of Dexamethasone caused by Posaconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[28]
Levalbuterol	DM5YBO1	Minor	Increased risk of hypokalemia by the combination of Dexamethasone and Levalbuterol.	Asthma [CA23]	[29]
Pirbuterol	DMI5678	Minor	Increased risk of hypokalemia by the combination of Dexamethasone and Pirbuterol.	Asthma [CA23]	[28]
Roflumilast	DMPGHY8	Moderate	Additive immunosuppressive effects by the combination of Dexamethasone and Roflumilast.	Asthma [CA23]	[26]
Dalfopristin	DM4LTKV	Moderate	Decreased metabolism of Dexamethasone caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[30]
ABT-492	DMJFD2I	Major	Increased risk of tendinitis/tendon rupture by the combination of Dexamethasone and ABT-492.	Bacterial infection [1A00-1C4Z]	[31]
Troleandomycin	DMUZNIG	Moderate	Decreased metabolism of Dexamethasone caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[32]
Pexidartinib	DMS2J0Z	Moderate	Increased metabolism of Dexamethasone caused by Pexidartinib mediated induction of CYP450 enzyme.	Bone/articular cartilage neoplasm [2F7B]	[33]
Ixabepilone	DM2OZ3G	Moderate	Increased metabolism of Dexamethasone caused by Ixabepilone mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[34]
Lapatinib	DM3BH1Y	Moderate	Increased metabolism of Dexamethasone caused by Lapatinib mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[29]
HKI-272	DM6QOVN	Major	Increased metabolism of Dexamethasone caused by HKI-272 mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[29]
LY2835219	DM93VBZ	Moderate	Increased metabolism of Dexamethasone caused by LY2835219 mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[35]
Tucatinib	DMBESUA	Moderate	Increased metabolism of Dexamethasone caused by Tucatinib mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[36]
Palbociclib	DMD7L94	Moderate	Increased metabolism of Dexamethasone caused by Palbociclib mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[29]
Bosutinib	DMTI8YE	Major	Increased metabolism of Dexamethasone caused by Bosutinib mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[37]
Macitentan	DMP79A1	Moderate	Increased metabolism of Dexamethasone caused by Macitentan mediated induction of CYP450 enzyme.	Cardiovascular disease [BA00-BE2Z]	[38]
PF-04449913	DMSB068	Major	Increased metabolism of Dexamethasone caused by PF-04449913 mediated induction of CYP450 enzyme.	Chronic myelomonocytic leukaemia [2A40]	[39]
Vilanterol	DMF5EK1	Minor	Increased risk of hypokalemia by the combination of Dexamethasone and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[29]
Indacaterol	DMQJHR7	Minor	Increased risk of hypokalemia by the combination of Dexamethasone and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[28]
Arformoterol	DMYM974	Minor	Increased risk of hypokalemia by the combination of Dexamethasone and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[28]
Dihydrocodeine	DMB0FWL	Moderate	Increased metabolism of Dexamethasone caused by Dihydrocodeine mediated induction of CYP450 enzyme.	Chronic pain [MG30]	[40]
Regorafenib	DMHSY1I	Moderate	Increased metabolism of Dexamethasone caused by Regorafenib mediated induction of CYP450 enzyme.	Colorectal cancer [2B91]	[41]
Intedanib	DMSTA36	Major	Increased metabolism of Dexamethasone caused by Intedanib mediated induction of CYP450 enzyme.	Colorectal cancer [2B91]	[42]
Pancuronium	DMB0VY8	Moderate	Additive neuromuscular blocking effects by the combination of Dexamethasone and Pancuronium.	Corneal disease [9A76-9A78]	[28]
Osilodrostat	DMIJC9X	Moderate	Increased metabolism of Dexamethasone caused by Osilodrostat mediated induction of CYP450 enzyme.	Cushing syndrome [5A70]	[43]
Ivacaftor	DMZC1HS	Moderate	Increased metabolism of Dexamethasone caused by Ivacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[44]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Dexamethasone caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[45]
Rivaroxaban	DMQMBZ1	Moderate	Increased metabolism of Dexamethasone caused by Rivaroxaban mediated induction of CYP450 enzyme.	Deep vein thrombosis [BD71]	[46]
Vilazodone	DM4LECQ	Moderate	Increased metabolism of Dexamethasone caused by Vilazodone mediated induction of CYP450 enzyme.	Depression [6A70-6A7Z]	[47]
Vortioxetine	DM6F1PU	Moderate	Increased metabolism of Dexamethasone caused by Vortioxetine mediated induction of CYP450 enzyme.	Depression [6A70-6A7Z]	[48]
Cenobamate	DM8KLU9	Moderate	Increased metabolism of Dexamethasone caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[49]
Stiripentol	DMMSDOY	Moderate	Increased metabolism of Dexamethasone caused by Stiripentol mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[26]
Fosphenytoin	DMOX3LB	Moderate	Increased metabolism of Dexamethasone caused by Fosphenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[50]
Tazemetostat	DMWP1BH	Major	Increased metabolism of Dexamethasone caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[51]
Solifenacin	DMG592Q	Moderate	Increased metabolism of Dexamethasone caused by Solifenacin mediated induction of CYP450 enzyme.	Functional bladder disorder [GC50]	[52]
Mirabegron	DMS1GYT	Minor	Increased metabolism of Dexamethasone caused by Mirabegron mediated induction of CYP450 enzyme.	Functional bladder disorder [GC50]	[53]
Ripretinib	DM958QB	Moderate	Increased metabolism of Dexamethasone caused by Ripretinib mediated induction of CYP450 enzyme.	Gastrointestinal stromal tumour [2B5B]	[29]
Avapritinib	DMK2GZX	Major	Increased metabolism of Dexamethasone caused by Avapritinib mediated induction of CYP450 enzyme.	Gastrointestinal stromal tumour [2B5B]	[26]
Boceprevir	DMBSHMF	Moderate	Increased metabolism of Dexamethasone caused by Boceprevir mediated induction of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[54]
Simeprevir	DMLUA9D	Major	Increased metabolism of Dexamethasone caused by Simeprevir mediated induction of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[55]
Telaprevir	DMMRV29	Moderate	Increased metabolism of Dexamethasone caused by Telaprevir mediated induction of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[54]
Pretomanid	DMDYA31	Major	Increased metabolism of Dexamethasone caused by Pretomanid mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[56]
Fosamprenavir	DM4W9B3	Moderate	Decreased metabolism of Dexamethasone caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[29]
Cobicistat	DM6L4H2	Moderate	Decreased metabolism of Dexamethasone caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[29]
Dolutegravir	DMCZGRE	Minor	Increased metabolism of Dexamethasone caused by Dolutegravir mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[57]
Elvitegravir	DMG9B1U	Moderate	Increased metabolism of Dexamethasone caused by Elvitegravir mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[29]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Dexamethasone caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[58]
Rilpivirine	DMJ0QOW	Major	Increased metabolism of Dexamethasone caused by Rilpivirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[59]
Darunavir	DMN3GCH	Moderate	Decreased metabolism of Dexamethasone caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[32]
Maraviroc	DMTL94F	Moderate	Increased metabolism of Dexamethasone caused by Maraviroc mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[29]
Bempedoic acid	DM1CI9R	Major	Increased risk of tendinitis/tendon rupture by the combination of Dexamethasone and Bempedoic acid.	Hyper-lipoproteinaemia [5C80]	[60]
Tolvaptan	DMIWFRL	Moderate	Increased metabolism of Dexamethasone caused by Tolvaptan mediated induction of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[26]
Suvorexant	DM0E6S3	Moderate	Increased metabolism of Dexamethasone caused by Suvorexant mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[61]
Amobarbital	DM0GQ8N	Moderate	Increased metabolism of Dexamethasone caused by Amobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[62]
Tasimelteon	DMLOQ1V	Moderate	Increased metabolism of Dexamethasone caused by Tasimelteon mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[63]
ITI-007	DMUQ1DO	Major	Increased metabolism of Dexamethasone caused by ITI-007 mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[64]
Naloxegol	DML0B41	Moderate	Increased metabolism of Dexamethasone caused by Naloxegol mediated induction of CYP450 enzyme.	Large intestine motility disorder [DB32]	[65]
Pemigatinib	DM819JF	Major	Increased metabolism of Dexamethasone caused by Pemigatinib mediated induction of CYP450 enzyme.	Liver cancer [2C12]	[26]
Denosumab	DMNI0KO	Moderate	Additive immunosuppressive effects by the combination of Dexamethasone and Denosumab.	Low bone mass disorder [FB83]	[66]
Crizotinib	DM4F29C	Moderate	Increased metabolism of Dexamethasone caused by Crizotinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[67]
Brigatinib	DM7W94S	Major	Increased metabolism of Dexamethasone caused by Brigatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[29]
Ceritinib	DMB920Z	Moderate	Increased metabolism of Dexamethasone caused by Ceritinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[68]
Lurbinectedin	DMEFRTZ	Major	Decreased metabolism of Dexamethasone caused by Lurbinectedin mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[69]
PF-06463922	DMKM7EW	Major	Increased metabolism of Dexamethasone caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[70]
Osimertinib	DMRJLAT	Moderate	Increased metabolism of Dexamethasone caused by Osimertinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[71]
BIBW 2992	DMTKD7Q	Moderate	Accelerated clearance of Dexamethasone due to the transporter induction by BIBW 2992.	Lung cancer [2C25]	[72]
Pralsetinib	DMWU0I2	Moderate	Increased metabolism of Dexamethasone caused by Pralsetinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[73]
Capmatinib	DMYCXKL	Major	Increased metabolism of Dexamethasone caused by Capmatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[74]
Selpercatinib	DMZR15V	Major	Increased metabolism of Dexamethasone caused by Selpercatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[26]
Artemether	DM48QOT	Moderate	Increased metabolism of Dexamethasone caused by Artemether mediated induction of CYP450 enzyme.	Malaria [1F40-1F45]	[29]
Idelalisib	DM602WT	Moderate	Increased metabolism of Dexamethasone caused by Idelalisib mediated induction of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[75]
GDC-0199	DMH0QKA	Major	Increased metabolism of Dexamethasone caused by GDC-0199 mediated induction of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[76]
IPI-145	DMWA24P	Moderate	Increased metabolism of Dexamethasone caused by IPI-145 mediated induction of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[77]
Acalabrutinib	DM7GCVW	Moderate	Increased metabolism of Dexamethasone caused by Acalabrutinib mediated induction of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[78]
Ponatinib	DMYGJQO	Moderate	Increased metabolism of Dexamethasone caused by Ponatinib mediated induction of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[29]
Arry-162	DM1P6FR	Moderate	Increased metabolism of Dexamethasone caused by Arry-162 mediated induction of CYP450 enzyme.	Melanoma [2C30]	[29]
Vemurafenib	DM62UG5	Moderate	Increased metabolism of Dexamethasone caused by Vemurafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[79]
Nivolumab	DMAB9QE	Moderate	Additive immunosuppressive effects by the combination of Dexamethasone and Nivolumab.	Melanoma [2C30]	[28]
Selumetinib	DMC7W6R	Major	Increased metabolism of Dexamethasone caused by Selumetinib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[80]
Pembrolizumab	DMFQEA6	Moderate	Additive immunosuppressive effects by the combination of Dexamethasone and Pembrolizumab.	Melanoma [2C30]	[28]
Ipilimumab	DMJTIYK	Moderate	Additive immunosuppressive effects by the combination of Dexamethasone and Ipilimumab.	Melanoma [2C30]	[28]
Cemiplimab	DMKMJHE	Moderate	Additive immunosuppressive effects by the combination of Dexamethasone and Cemiplimab.	Melanoma [2C30]	[28]
LGX818	DMNQXV8	Major	Increased metabolism of Dexamethasone caused by LGX818 mediated induction of CYP450 enzyme.	Melanoma [2C30]	[81]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Dexamethasone caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[26]
Ubrogepant	DM749I3	Moderate	Increased metabolism of Dexamethasone caused by Ubrogepant mediated induction of CYP450 enzyme.	Migraine [8A80]	[82]
Rimegepant	DMHOAUG	Major	Increased metabolism of Dexamethasone caused by Rimegepant mediated induction of CYP450 enzyme.	Migraine [8A80]	[83]
Flibanserin	DM70DTN	Moderate	Increased metabolism of Dexamethasone caused by Flibanserin mediated induction of CYP450 enzyme.	Mood disorder [6A60-6E23]	[84]
Panobinostat	DM58WKG	Moderate	Increased metabolism of Dexamethasone caused by Panobinostat mediated induction of CYP450 enzyme.	Multiple myeloma [2A83]	[85]
Tecfidera	DM2OVDT	Moderate	Additive immunosuppressive effects by the combination of Dexamethasone and Tecfidera.	Multiple sclerosis [8A40]	[86]
Siponimod	DM2R86O	Major	Increased metabolism of Dexamethasone caused by Siponimod mediated induction of CYP450 enzyme.	Multiple sclerosis [8A40]	[29]
Fingolimod	DM5JVAN	Major	Additive immunosuppressive effects by the combination of Dexamethasone and Fingolimod.	Multiple sclerosis [8A40]	[87]
Ocrelizumab	DMEZ2KH	Moderate	Additive immunosuppressive effects by the combination of Dexamethasone and Ocrelizumab.	Multiple sclerosis [8A40]	[88]
Romidepsin	DMT5GNL	Moderate	Increased metabolism of Dexamethasone caused by Romidepsin mediated induction of CYP450 enzyme.	Mycosis fungoides [2B01]	[89]
Fedratinib	DM4ZBK6	Major	Increased metabolism of Dexamethasone caused by Fedratinib mediated induction of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[26]
Nilotinib	DM7HXWT	Major	Increased metabolism of Dexamethasone caused by Nilotinib mediated induction of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[90]
Ruxolitinib	DM7Q98D	Moderate	Increased metabolism of Dexamethasone caused by Ruxolitinib mediated induction of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[91]
Omacetaxine mepesuccinate	DMPU2WX	Moderate	Additive immunosuppressive effects by the combination of Dexamethasone and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[92]
Rolapitant	DM8XP26	Moderate	Increased metabolism of Dexamethasone caused by Rolapitant mediated induction of CYP450 enzyme.	Nausea/vomiting [MD90]	[26]
Netupitant	DMEKAYI	Moderate	Decreased metabolism of Dexamethasone caused by Netupitant mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[93]
E-2007	DMJDYNQ	Moderate	Increased metabolism of Dexamethasone caused by E-2007 mediated induction of CYP450 enzyme.	Neuropathy [8C0Z]	[26]
Atezolizumab	DMMF8U0	Moderate	Additive immunosuppressive effects by the combination of Dexamethasone and Atezolizumab.	Non-small cell lung cancer [2C25]	[28]
Entrectinib	DMMPTLH	Major	Increased metabolism of Dexamethasone caused by Entrectinib mediated induction of CYP450 enzyme.	Non-small cell lung cancer [2C25]	[94]
S-297995	DM26IH8	Moderate	Increased metabolism of Dexamethasone caused by S-297995 mediated induction of CYP450 enzyme.	Opioid use disorder [6C43]	[26]
Olaparib	DM8QB1D	Major	Increased metabolism of Dexamethasone caused by Olaparib mediated induction of CYP450 enzyme.	Ovarian cancer [2C73]	[29]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Dexamethasone caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[95]
Pimavanserin	DMR7IVC	Moderate	Increased metabolism of Dexamethasone caused by Pimavanserin mediated induction of CYP450 enzyme.	Parkinsonism [8A00]	[96]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Dexamethasone caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[97]
Lefamulin	DME6G97	Major	Increased metabolism of Dexamethasone caused by Lefamulin mediated induction of CYP450 enzyme.	Pneumonia [CA40]	[98]
Choline salicylate	DM8P137	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Dexamethasone and Choline salicylate.	Postoperative inflammation [1A00-CA43]	[20]
Ergonovine	DM0VEC1	Moderate	Increased metabolism of Dexamethasone caused by Ergonovine mediated induction of CYP450 enzyme.	Postpartum haemorrhage [JA43]	[29]
Lonafarnib	DMGM2Z6	Major	Increased metabolism of Dexamethasone caused by Lonafarnib mediated induction of CYP450 enzyme.	Premature ageing appearance [LD2B]	[99]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Dexamethasone caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[100]
Relugolix	DMK7IWL	Moderate	Accelerated clearance of Dexamethasone due to the transporter induction by Relugolix.	Prostate cancer [2C82]	[101]
Darolutamide	DMV7YFT	Major	Increased metabolism of Dexamethasone caused by Darolutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[102]
Silodosin	DMJSBT6	Moderate	Increased metabolism of Dexamethasone caused by Silodosin mediated induction of CYP450 enzyme.	Prostate hyperplasia [GA90]	[29]
Apremilast	DMTWS9E	Moderate	Increased metabolism of Dexamethasone caused by Apremilast mediated induction of CYP450 enzyme.	Psoriasis [EA90]	[103]
Riociguat	DMXBLMP	Moderate	Increased metabolism of Dexamethasone caused by Riociguat mediated induction of CYP450 enzyme.	Pulmonary hypertension [BB01]	[104]
Everolimus	DM8X2EH	Major	Increased metabolism of Dexamethasone caused by Everolimus mediated induction of CYP450 enzyme.	Renal cell carcinoma [2C90]	[25]
Axitinib	DMGVH6N	Major	Increased metabolism of Dexamethasone caused by Axitinib mediated induction of CYP450 enzyme.	Renal cell carcinoma [2C90]	[105]
Temsirolimus	DMS104F	Major	Increased metabolism of Dexamethasone caused by Temsirolimus mediated induction of CYP450 enzyme.	Renal cell carcinoma [2C90]	[29]
Aripiprazole	DM3NUMH	Moderate	Increased metabolism of Dexamethasone caused by Aripiprazole mediated induction of CYP450 enzyme.	Schizophrenia [6A20]	[106]
Anthrax vaccine	DM9GSWY	Moderate	Antagonize the effect of Dexamethasone when combined with Anthrax vaccine.	Sepsis [1G40-1G41]	[107]
Avanafil	DM75CXN	Moderate	Increased metabolism of Dexamethasone caused by Avanafil mediated induction of CYP450 enzyme.	Sexual dysfunction [HA00-HA01]	[108]
Voxelotor	DMCS6M5	Major	Increased metabolism of Dexamethasone caused by Voxelotor mediated induction of CYP450 enzyme.	Sickle-cell disorder [3A51]	[109]
LDE225	DMM9F25	Major	Increased metabolism of Dexamethasone caused by LDE225 mediated induction of CYP450 enzyme.	Skin cancer [2C30-2C37]	[110]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Dexamethasone caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[26]
Larotrectinib	DM26CQR	Moderate	Increased metabolism of Dexamethasone caused by Larotrectinib mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[29]
Trabectedin	DMG3Y89	Moderate	Increased metabolism of Dexamethasone caused by Trabectedin mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[26]
Armodafinil	DMGB035	Moderate	Increased metabolism of Dexamethasone caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[111]
LEE011	DMMX75K	Moderate	Increased metabolism of Dexamethasone caused by LEE011 mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[29]
Vandetanib	DMRICNP	Moderate	Increased metabolism of Dexamethasone caused by Vandetanib mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[112]
Pitolisant	DM8RFNJ	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Dexamethasone and Pitolisant.	Somnolence [MG42]	[26]
Fostamatinib	DM6AUHV	Moderate	Increased metabolism of Dexamethasone caused by Fostamatinib mediated induction of CYP450 enzyme.	Thrombocytopenia [3B64]	[113]
Apixaban	DM89JLN	Moderate	Increased metabolism of Dexamethasone caused by Apixaban mediated induction of CYP450 enzyme.	Thrombosis [DB61-GB90]	[114]
Brilinta	DMBR01X	Moderate	Increased metabolism of Dexamethasone caused by Brilinta mediated induction of CYP450 enzyme.	Thrombosis [DB61-GB90]	[25]
Cabozantinib	DMIYDT4	Moderate	Increased metabolism of Dexamethasone caused by Cabozantinib mediated induction of CYP450 enzyme.	Thyroid cancer [2D10]	[115]
Pipecuronium	DM5F84A	Moderate	Additive neuromuscular blocking effects by the combination of Dexamethasone and Pipecuronium.	Tonus and reflex abnormality [MB47]	[28]
Vecuronium	DMP0UK2	Moderate	Additive neuromuscular blocking effects by the combination of Dexamethasone and Vecuronium.	Tonus and reflex abnormality [MB47]	[28]
Linagliptin	DMWFJTR	Moderate	Increased metabolism of Dexamethasone caused by Linagliptin mediated induction of CYP450 enzyme.	Type 2 diabetes mellitus [5A11]	[116]
Durvalumab	DM4PVDY	Moderate	Additive immunosuppressive effects by the combination of Dexamethasone and Durvalumab.	Ureteral cancer [2C92]	[28]
Elagolix	DMB2C0E	Moderate	Increased metabolism of Dexamethasone caused by Elagolix mediated induction of CYP450 enzyme.	Uterine fibroid [2E86]	[117]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
FD&C blue no. 1	E00263	19700	Colorant
Hydrazine yellow	E00409	164825	Colorant
Quinoline yellow WS	E00309	24671	Colorant
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Carmellose sodium	E00625	Not Available	Disintegrant
Dextrin	E00359	62698	Binding agent; Diluent; Microencapsulating agent; Stiffening agent; Suspending agent; Viscosity-controlling agent
FD&C red no. 3	E00629	Not Available	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Saccharose	E00091	5988	Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Dexamethasone 6 mg tablet	6 mg	Oral Tablet	Oral
Dexamethasone 0.5 mg tablet	0.5 mg	Oral Tablet	Oral
Dexamethasone 0.75 mg tablet	0.75 mg	Oral Tablet	Oral
Dexamethasone 1.5 mg tablet	1.5 mg	Oral Tablet	Oral
Dexamethasone 4 mg tablet	4 mg	Oral Tablet	Oral
Dexamethasone 1 mg tablet	1 mg	Oral Tablet	Oral
Dexamethasone 2 mg tablet	2 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] Dexamethasone FDA Label
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3447).
• [3] Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. N Engl J Med. 2020 Jul 17. doi: 10.1056/NEJMoa2021436.
• [4] BDDCS applied to over 900 drugs
• [5] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [6] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [7] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [8] Interaction between the glucocorticoid and erythropoietin receptors in human erythroid cells. Exp Hematol. 2009 May;37(5):559-72.
• [9] Peptide transporter substrate identification during permeability screening in drug discovery: comparison of transfected MDCK-hPepT1 cells to Caco-2 cells. Arch Pharm Res. 2007 Apr;30(4):507-18.
• [10] Modulation of drug-stimulated ATPase activity of human MDR1/P-glycoprotein by cholesterol. Biochem J. 2007 Jan 15;401(2):597-605.
• [11] Identification of drugs inhibiting the in vitro metabolism of tacrolimus by human liver microsomes. Br J Clin Pharmacol. 1996 Mar;41(3):187-90.
• [12] Regulation of CYP3A5 by glucocorticoids and cigarette smoke in human lung-derived cells. J Pharmacol Exp Ther. 2003 Feb;304(2):745-52.
• [13] Cytotoxicity of chloroacetanilide herbicide alachlor in HepG2 cells independent of CYP3A4 and CYP3A7. Food Chem Toxicol. 2007 May;45(5):871-7.
• [14] Metabolism of synthetic steroids by the human placenta. Placenta. 2007 Jan;28(1):39-46.
• [15] In vitro metabolism of dexamethasone cipecilate, a novel synthetic corticosteroid, in human liver and nasal mucosa. Xenobiotica. 2011 Oct;41(10):874-84.
• [16] Identification of mechanisms of action of bisphenol a-induced human preadipocyte differentiation by transcriptional profiling. Obesity (Silver Spring). 2014 Nov;22(11):2333-43.
• [17] Dexamethasone and the inflammatory response in explants of human omental adipose tissue. Mol Cell Endocrinol. 2010 Feb 5;315(1-2):292-8.
• [18] SGK1, a potential regulator of c-fms related breast cancer aggressiveness. Clin Exp Metastasis. 2004;21(6):477-83.
• [19] Inhibition of PARP1 Increases IRF-dependent Gene Transcription in Jurkat Cells. Curr Med Sci. 2019 Jun;39(3):356-362. doi: 10.1007/s11596-019-2043-1. Epub 2019 Jun 17.
• [20] Baer PA, Shore A, Ikeman RL "Transient fall in serum salicylate levels following intraarticular injection of steroid in patients with rheumatoid arthritis." Arthritis Rheum 30 (1987): 345-7. [PMID: 3566826]
• [21] Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
• [22] Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
• [23] Albin H, Vincon G, Demotes-Mainard F, et al "Effect of aluminium phosphate on the bioavailability of cimetidine and prednisolone." Eur J Clin Pharmacol 26 (1984): 271-3. [PMID: 6723769]
• [24] Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
• [25] Canadian Pharmacists Association.
• [26] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [27] Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
• [28] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
• [29] Cerner Multum, Inc. "Australian Product Information.".
• [30] Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA.
• [31] FDA. U.S. Food and Drug Administration "Information for Healthcare Professionals. Fluoroquinolone Antimicrobial Drugs. FDA Alert [7/8/2008].".
• [32] Edsbacker S, Andersson T "Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease." Clin Pharmacokinet 43 (2004): 803-21. [PMID: 15355126]
• [33] Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
• [34] Product Information. Ixempra (ixabepilone). Bristol-Myers Squibb, Princeton, NJ.
• [35] Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
• [36] Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
• [37] Product Information. Bosulif (bosutinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [38] Bruderer S, Aanismaa P, Homery MC, et al. "Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist." AAPS J 14 (2012): 68-78. [PMID: 22189899]
• [39] Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [40] Caraco Y, Sheller J, Wood AJ "Pharmacogenetic determinants of codeine induction by rifampin: the impact on codeine's respiratory, psychomotor and miotic effects." J Pharmacol Exp Ther 281 (1997): 330-6. [PMID: 9103514]
• [41] Product Information. Stivarga (regorafenib). Bayer Pharmaceutical Inc, West Haven, CT.
• [42] Product Information. Ofev (nintedanib). Boehringer Ingelheim, Ridgefield, CT.
• [43] Product Information. Isturisa (osilodrostat). Recordati Rare Diseases Inc, Lebanon, NJ.
• [44] Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
• [45] Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
• [46] Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
• [47] Product Information. Viibryd (vilazodone). Trovis Pharmaceuticals LLC, New Haven, CT.
• [48] Product Information. Brintellix (vortioxetine). Takeda Pharmaceuticals America, Lincolnshire, IL.
• [49] Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
• [50] Frey BM, Frey FJ "Phenytoin modulates the pharmacokinetics of prednisolone and the pharmacodynamics of prednisolone as assessed by the inhibition of the mixed lymphocyte reaction in humans." Eur J Clin Invest 14 (1984): 1-6. [PMID: 6230241]
• [51] Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
• [52] Product Information. VESIcare (solifenacin). GlaxoSmithKline, Research Triangle Park, NC.
• [53] Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
• [54] Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
• [55] Product Information. Olysio (simeprevir). Janssen Pharmaceuticals, Titusville, NJ.
• [56] Product Information. Pretomanid (pretomanid). The Global Alliance for TB Drug Development, New York, NY.
• [57] Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
• [58] Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
• [59] Product Information. Edurant (rilpivirine). Tibotec Pharmaceuticals, Titusville, NJ.
• [60] Product Information. Nexletol (bempedoic acid). Esperion Therapeutics, Ann Arbor, MI.
• [61] Product Information. Belsomra (suvorexant). Merck & Company Inc, Whitehouse Station, NJ.
• [62] Bartoszek M, Brenner AM, Szefler SJ "Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy." Clin Pharmacol Ther 42 (1987): 424-32. [PMID: 3665340]
• [63] Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
• [64] Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
• [65] Product Information. Movantik (naloxegol). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
• [66] Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
• [67] Cerner Multum, Inc. "Canadian Product Information.".
• [68] Product Information. Zykadia (ceritinib). Novartis Pharmaceuticals, East Hanover, NJ.
• [69] Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
• [70] Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [71] Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
• [72] Product Information. Gilotrif (afatinib). Boehringer Ingelheim, Ridgefield, CT.
• [73] Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
• [74] Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
• [75] Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
• [76] Product Information. Venclexta (venetoclax). AbbVie US LLC, North Chicago, IL.
• [77] Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
• [78] Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
• [79] Product Information. Zelboraf (vemurafenib). Genentech, South San Francisco, CA.
• [80] Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
• [81] Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
• [82] Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
• [83] Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
• [84] Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
• [85] Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
• [86] Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
• [87] Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
• [88] Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
• [89] Product Information. Istodax (romidepsin). Gloucester Pharmaceuticals, Cambridge, MA.
• [90] Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
• [91] Product Information. Jakafi (ruxolitinib). Incyte Corporation, Wilmington, DE.
• [92] Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
• [93] Product Information. Akynzeo (netupitant-palonosetron). Eisai Inc, Woodcliff Lake, NJ.
• [94] Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA.
• [95] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
• [96] Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
• [97] Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
• [98] Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
• [99] Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
• [100] Product Information. Xtandi (enzalutamide). Astellas Pharma US, Inc, Deerfield, IL.
• [101] Product Information. Orgovyx (relugolix). Myovant Sciences, Inc., Brisbane, CA.
• [102] Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
• [103] Product Information. Otezla (apremilast). Celgene Corporation, Summit, NJ.
• [104] Product Information. Adempas (riociguat). Bayer Pharmaceutical Inc, West Haven, CT.
• [105] Pithavala YK, Tortorici M, Toh M, et al "Effect of rifampin on the pharmacokinetics of axitinib (AG-013736) in Japanese and Caucasian healthy volunteers." Cancer Chemother Pharmacol 65 (2010): 563-70. [PMID: 19603168]
• [106] Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.
• [107] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
• [108] Product Information. Stendra (avanafil). Vivus Inc, Mountain View, CA.
• [109] Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
• [110] Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
• [111] Product Information. Nuvigil (armodafinil). Cephalon Inc, West Chester, PA.
• [112] Martin P, Oliver S, Robertson J, Kennedy SJ, Read J, Duvauchelle T "Pharmacokinetic drug interactions with vandetanib during cadministration with rifampicin or itraconazole." Drugs R D 11 (2011): 37-51. [PMID: 21410294]
• [113] Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
• [114] Product Information. Eliquis (apixaban). Bristol-Myers Squibb Canada Inc, Montreal, IN.
• [115] Product Information. Cabometyx (cabozantinib). Exelixis Inc, S San Francisco, CA.
• [116] Product Information. Tradjenta (linagliptin). Boehringer Ingelheim, Ridgefield, CT.
• [117] Product Information. Orilissa (elagolix). AbbVie US LLC, North Chicago, IL.